

Supporting Information

Inter and Intramolecular Mitsunobu Reaction and Metal Complexation Study: Synthesis of *S*-Amino Acids Derived Chiral 1,2,3,4-Tetrahydroquinoxaline, Benzo annulated [9]-N₃ Peraza, [12]-N₄ Peraza-Macrocycles†

Krishnananda Samanta, Nitin Srivastava, Satyen Saha and Gautam Panda*

1. Contents	1-12
2. Spectra	13-180
3. characterization data of selected examples	181-199

Fig. S-1: ¹H Spectra of (2*S*)-2-(2-Nitrophenylamino)propionic Acid Methyl Ester (**3a**).

Fig. S-2: ¹³C Spectra of (2*S*)-2-(2-Nitrophenylamino)propionic Acid Methyl Ester (**3a**).

Fig. S-3: ¹H Spectra of (2*S*)-2-(2-Nitrophenylamino)-3-phenylpropionic Acid Methyl Ester (**3b**).

Fig. S-4: ¹³C Spectra of (2*S*)-2-(2-Nitrophenylamino)-3-phenylpropionic Acid Methyl Ester (**3b**).

Fig. S-5: HPLC Spectra of (2*S*)-2-(2-Nitrophenylamino)-3-phenylpropionic Acid Methyl Ester (**3b**) and its enantiomer.

Fig. S-6: HPLC Spectra of (2*S*)-2-(2-Nitrophenylamino)-3-phenylpropionic Acid Methyl Ester (**3b**).

Fig. S-7: ¹H Spectra of (2*S*)-4-Methyl-2-(2-nitrophenylamino)pentanoic Acid Methyl Ester (**3c**).

Fig. S-8: ^{13}C Spectra of (2*S*)-4-Methyl-2-(2-nitrophenylamino)pentanoic Acid Methyl Ester (**3c**).

Fig. S-9: ^1H Spectra of (2*S*,3*S*)-Methyl-3-methyl-2-(2-nitrophenylamino)pentanoic Acid Methyl Ester (**3d**).

Fig. S-10: ^{13}C Spectra of (2*S*,3*S*)-Methyl-3-methyl-2-(2-nitrophenylamino)pentanoic Acid Methyl Ester (**3d**).

Fig. S-11: ^1H Spectra of (2*S*)-3-(1*H*-Indol-3-yl)-2-(2-nitrophenylamino)propionic Acid Methyl Ester (**3e**).

Fig. S-12: ^{13}C Spectra of (2*S*)-3-(1*H*-Indol-3-yl)-2-(2-nitrophenylamino)propionic Acid Methyl Ester (**3e**).

Fig. S-13: ^1H Spectra of (2*S*)-3-Methyl-2-(2-nitrophenylamino)butyric Acid Methyl Ester (**3f**).

Fig. S-14: ^{13}C Spectra of (2*S*)-3-Methyl-2-(2-nitrophenylamino)butyric Acid Methyl Ester (**3f**).

Fig. S-15: HPLC Spectra of (2*S*)-3-Methyl-2-(2-nitrophenylamino)butyric Acid Methyl Ester (**3f**).

Fig. S-16: ^1H Spectra of (2*S*)-4-Methylsulfanyl-2-(2-nitrophenylamino)butyric Acid Methyl Ester (**3g**).

Fig. S-17: ^{13}C Spectra of (2*S*)-4-Methylsulfanyl-2-(2-nitrophenylamino)butyric Acid Methyl Ester (**3g**).

Fig. S-18: ^1H Spectra of (2*S*)-2-(2-Aminophenylamino)propan-1-ol (**4a**).

Fig. S-19: ^{13}C Spectra of (2*S*)-2-(2-Aminophenylamino)propan-1-ol (**4a**).

Fig. S-20: ^1H Spectra of (2*S*)-2-(2-Aminophenylamino)-3-phenylpropan-1-ol (**4b**).

Fig. S-21: ^{13}C Spectra of (2*S*)-2-(2-Aminophenylamino)-3-phenylpropan-1-ol (**4b**).

Fig. S-22: ^1H Spectra of (2*S*)-2-(2-Aminophenylamino)-4-methylpentan-1-ol (**4c**).

Fig. S-23: ^{13}C Spectra of (2*S*)-2-(2-Aminophenylamino)-4-methylpentan-1-ol (**4c**).

Fig. S-24: ^1H Spectra of (2*S*,3*S*)-2-(2-Aminophenylamino)-3-methylpentan-1-ol (**4d**).

Fig. S-25: ^{13}C Spectra of (2*S*)- 2-(2-Aminophenylamino)-3-methylpentan-1-ol (**4d**).

Fig. S-26: ^1H Spectra of (2*S*)- 2-(2-Aminophenylamino)-3-(1*H*-Indol-3-yl)-propan-1-ol (**4e**).

Fig. S-27: ^{13}C Spectra of (2*S*)- 2-(2-Aminophenylamino)-3-(1*H*-Indol-3-yl)-propan-1-ol (**4e**).

Fig. S-28: ^1H Spectra of (2*S*)-2-(2-Aminophenylamino)-3-methylbutan-1-ol (**4f**).

Fig. S-29: ^{13}C Spectra of (2*S*)-2-(2-Aminophenylamino)-3-methylbutan-1-ol (**4f**).

Fig. S-30: ^1H Spectra of (2*S*)- 2-(2-Aminophenylamino)-4-methylsulfanylbutan-1-ol (**4g**).

Fig. S-31: ^{13}C Spectra of (2*S*)- 2-(2-Aminophenylamino)-4-methylsulfanylbutan-1-ol (**4g**).

Fig. S-32: ^1H Spectra of (1*S*)-*N*-[2-(2-Hydroxy-1-methylethylamino)phenyl]-4-methylbenzenesulfonamide (**5a**).

Fig. S-33: ^{13}C Spectra of (1*S*)-*N*-[2-(2-Hydroxy-1-methylethylamino)phenyl]-4-methylbenzenesulfonamide (**5a**).

Fig. S-34: ^1H Spectra of (1*S*)-*N*-[2-(1-Hydroxymethyl-2-phenylethylamino)phenyl]-4-methyl benzenesulfonamide (**5b**).

Fig. S-35: ^{13}C Spectra of (1*S*)-*N*-[2-(1-Hydroxymethyl-2-phenylethylamino)phenyl]-4-methyl benzenesulfonamide (**5b**).

Fig. S-36: ^1H Spectra of (1*S*)-*N*-[2-(1-Hydroxymethyl-3-methyl-butylamino)phenyl]-4-methylbenzenesulfonamide (**5c**).

Fig. S-37: ^{13}C Spectra of (1*S*)-*N*-[2-(1-Hydroxymethyl-3-methyl-butylamino)phenyl]-4-methylbenzenesulfonamide (**5c**).

Fig. S-38: ^1H Spectra of *N*-(2-((2*S*,3*S*)-1-Hydroxy-3-methylpentan-2-ylamino)phenyl)-4-methylbenzenesulfonamide (**5d**).

Fig. S-39: ^{13}C Spectra of *N*-(2-((2*S*,3*S*)-1-Hydroxy-3-methylpentan-2-ylamino)phenyl)-4-methylbenzenesulfonamide (**5d**).

Fig. S-40: ^1H Spectra of (1*S*)-*N*-{2-[1-Hydroxymethyl-2-(1*H*-indol-3-yl)-ethylamino]phenyl}-4-methylbenzenesulfonamide (**5e**).

Fig. S-41: ^{13}C Spectra of (1*S*)-*N*-{2-[1-Hydroxymethyl-2-(1*H*-indol-3-yl)-ethylamino]phenyl}-4-methylbenzenesulfonamide (**5e**).

Fig. S-42: ^1H Spectra of (1S)-N-[2-(1-Hydroxymethyl-2-methylpropylamino)phenyl]-4-methylbenzenesulfonamide (**5f**).

Fig. S-43: ^{13}C Spectra of (1S)-N-[2-(1-Hydroxymethyl-2-methylpropylamino)phenyl]-4-methylbenzenesulfonamide (**5f**).

Fig. S-44: ^1H Spectra of (1S)-N-[2-(1-Hydroxymethyl-3-methylsulfanylpropylamino)phenyl]-4-methylbenzenesulfonamide (**5g**).

Fig. S-45: ^{13}C Spectra of (1S)-N-[2-(1-Hydroxymethyl-3-methylsulfanylpropylamino)phenyl]-4-methylbenzenesulfonamide (**5g**).

Fig. S-46: ^1H Spectra of (3S)-3-Methyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6a**).

Fig. S-47: ^{13}C Spectra of (3S)-3-Methyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6a**).

Fig. S-48: HPLC Spectra of (3S)-3-Methyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6a**).

Fig. S-49: ^1H Spectra of (3S)-3-Benzyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6b**).

Fig. S-50: ^{13}C Spectra of (3S)-3-Benzyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6b**).

Fig. S-51: HPLC Spectra of (3S)-3-Benzyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6b**).

Fig. S-52: ^1H Spectra of (3S)-3-isoButyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6c**).

Fig. S-53: ^{13}C Spectra of (3S)-3-isoButyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6c**).

Fig. S-54: HPLC Spectra of (3S)-3-isoButyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6c**).

Fig. S-55: ^1H Spectra of (3S,4S)-3-secButyl-1-tosyl-1,2,3,4-Tetrahydroquinoxaline (**6d**).

Fig. S-56: ^{13}C Spectra of (3S,4S)-3-secButyl-1-tosyl-1,2,3,4-Tetrahydroquinoxaline (**6d**).

Fig. S-57: HPLC Spectra of (3S,4S)-3-secButyl-1-tosyl-1,2,3,4-Tetrahydroquinoxaline (**6d**).

Fig. S-58: ^1H Spectra of (3S)-3-(1*H*-Indol-3-ylmethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6e**).

Fig. S-59 ^{13}C Spectra of (3S)-3-(1*H*-Indol-3-ylmethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6e**).

Fig. S-60: HPLC Spectra of (3*S*)-3-(1*H*-Indol-3-ylmethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6e**).

Fig. S-61: ¹H Spectra of (3*S*)-3-isoPropyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6f**).

Fig. S-62: ¹³C Spectra of (3*S*)-3-isoPropyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6f**).

Fig. S-63: HPLC Spectra for mixture of (3*S*)-3-isoPropyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6f**) and its enantiomer.

Fig. S-64: HPLC Spectra of pure (3*S*)-3-isoPropyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6f**) .

Fig. S-65: HPLC Spectra for co-injection of racemic plus (3*S*)-3-isoPropyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6f**).

Fig. S-66: ¹H Spectra of (3*S*)-3-(2-Methylsulfanylethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6g**).

Fig. S-67: ¹³C Spectra of (3*S*)-3-(2-Methylsulfanylethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6g**).

Fig. S-68: HPLC Spectra of (3*S*)-3-(2-Methylsulfanylethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (**6g**).

Fig. S-69: ¹H Spectra of (S)-2-(2-Nitro-phenylamino)-propan-1-ol (**7a**).

Fig. S-70: ¹³C Spectra of (S)-2-(2-Nitro-phenylamino)-propan-1-ol (**7a**).

Fig. S-71: ¹H Spectra of (3*S*)-2-(2-Nitrophenylamino)-3-phenylpropan-1-ol (**7b**).

Fig. S-72: ¹³C Spectra of (3*S*)-2-(2-Nitrophenylamino)-3-phenylpropan-1-ol (**7b**).

Fig. S-73: ¹H Spectra of (S)-3-Methyl-2-(2-nitro-phenylamino)-butan-1-ol (**7c**).

Fig. S-74: ¹³C Spectra of (S)-3-Methyl-2-(2-nitro-phenylamino)-butan-1-ol (**7c**).

Fig. S-75: ¹H Spectra of (S)-2-Methyl-1,2,3,4-tetrahydroquinoxaline (**8a**).

Fig. S-76: ¹³C Spectra of (S)-2-Methyl-1,2,3,4-tetrahydroquinoxaline (**8a**).

Fig. S-77: ^1H Spectra of (S)-2-Benzyl-1,2,3,4-tetrahydroquinoxaline (**8b**).

Fig. S-78: ^{13}C Spectra of (S)-2-Benzyl-1,2,3,4-tetrahydroquinoxaline (**8b**).

Fig. S-79: HPLC Spectra of (S)-2-Benzyl-1,2,3,4-tetrahydroquinoxaline (**8b**).

Fig. S-80: ^1H Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido) propanoate (**10a**).

Fig. S-81: ^{13}C Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido) propanoate (**10a**).

Fig. S-82: ^1H Spectra of (S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)butanoate (**10b**).

Fig. S-83: ^{13}C Spectra of (S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)butanoate (**10b**).

Fig. S-84: ^1H Spectra of (S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (**10c**).

Fig. S-85: ^{13}C Spectra of (S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (**10c**).

Fig. S-86: ^1H Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)-3-phenylpropanoate (**10d**).

Fig. S-87: ^{13}C Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)-3-phenylpropanoate **10d**.

Fig. S-88: ^1H Spectra of (S)-Methyl 2-(4-methyl-N-((S)-2-(2-nitrophenylamino)propyl) phenylsulfonamido) propanoate (**10e**).

Fig. S-89: ^{13}C Spectra of (S)-Methyl 2-(4-methyl-N-((S)-2-(2-nitrophenylamino)propyl) phenylsulfonamido) propanoate (**10e**).

Fig. S-90: ^1H Spectra of (S)-Methyl 3-methyl-2-(4-methyl-N-((S)-3-methyl-2-(2-nitrophenylamino)butyl) phenyl sulfonamido)butanoate (**10f**).

Fig. S-91: ^{13}C Spectra (S)-Methyl 3-methyl-2-(4-methyl-N-((S)-3-methyl-2-(2-nitrophenylamino)butyl) phenyl sulfonamido)butanoate (**10f**).

Fig. S-92: ^1H Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl) phenylsulfonamido)propanoate (**11a**).

Fig. S-93: ^{13}C Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl) phenylsulfonamido)propanoate (**11a**).

Fig. S-94: ^1H Spectra of (S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl) phenylsulfonamido)butanoate (**11b**).

Fig. S-95: ^{13}C Spectra of (S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl) phenylsulfonamido)butanoate (**11b**).

Fig. S-96: ^1H Spectra of (S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (**11c**).

Fig. S-97: ^{13}C Spectra of (S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (**11c**).

Fig. S-98: ^1H Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)- phenylsulfonamido)-3-phenylpropanoate (**11d**).

Fig. S-99: ^{13}C Spectra of (S)-Methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)- phenylsulfonamido)-3-phenylpropanoate (**11d**).

Fig. S-100: ^1H Spectra of N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**12b**).

Fig. S-101: ^{13}C Spectra of N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**12b**).

Fig. S-102: ^1H Spectra of N-((S)-1-Hydroxy-4-methylpentan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**12c**).

Fig. S-103: ^1H Spectra of N-((S)-1-Hydroxy-3-phenylpropan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**12d**).

Fig. S-104: ^{13}C Spectra of N-((S)-1-Hydroxy-3-phenylpropan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**12d**).

Fig. S-105: ^1H Spectra of N-((S)-1-Hydroxypropan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-propyl)benzenesulfonamide (**12e**).

Fig. S-106: ^{13}C Spectra of N-((S)-1-Hydroxypropan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-propyl)benzenesulfonamide (**12e**).

Fig. S-107: ^1H Spectra of N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-3-methyl-2-(2-(4-methylphenylsulfonamido)-phenylamino)butyl)benzenesulfonamide (**12f**).

Fig. S-108: ^{13}C Spectra of N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-3-methyl-2-(2-(4-methylphenylsulfonamido)-phenylamino)butyl)benzenesulfonamide (**12f**).

Fig. S-109: ^1H Spectra of (3S,6S)-6-Benzyl-3-methyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13a**).

Fig. S-110: ^{13}C Spectra of (3S,6S)-6-Benzyl-3-methyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13a**).

Fig. S-111: HPLC Spectra of (3S,6S)-6-Benzyl-3-methyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13a**).

Fig. S-112: ^1H Spectra of (3S,6S)-6-Benzyl-3-isopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13b**).

Fig. S-113: ^{13}C Spectra of (3S,6S)-6-Benzyl-3-isopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13b**).

Fig. S-114: HPLC Spectra for mixture of (3S,6S)-6-Benzyl-3-isopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13b**) and its enantiomer.

Fig. S-115: HPLC Spectra for pure (3S,6S)-6-Benzyl-3-isopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13b**).

Fig. S-116: ^1H Spectra of (3S,6S)-6-Benzyl-3-isobutyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13c**).

Fig. S-117: ^{13}C Spectra of (3S,6S)-6-Benzyl-3-isobutyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13c**).

Fig. S-118: HPLC Spectra of (3S,6S)-6-Benzyl-3-isobutyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13c**).

Fig. S-119: ^1H Spectra of (3S,6S)-3,6-Dibenzyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (**13d**).

- Fig. S-120:** ^{13}C Spectra of (3*S*,6*S*)-3,6-Dibenzyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**13d**).
- Fig. S-121:** HPLC Spectra of (3*S*,6*S*)-3,6-Dibenzyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**13d**).
- Fig. S-122:** ^1H Spectra of (3*S*,6*S*)-3,6-Dimethyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**13e**).
- Fig. S-123:** ^{13}C Spectra of (3*S*,6*S*)-3,6-Dimethyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**13e**).
- Fig. S-124:** ^1H Spectra of (3*S*,6*S*)-3,6-Diisopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**13f**).
- Fig. S-125:** ^{13}C Spectra of (3*S*,6*S*)-3,6-Diisopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**13f**).
- Fig. S-126:** ^1H Spectra of (2*S*,5*S*)-2-Benzyl-5-isopropyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14a**).
- Fig. S-127:** ^1H Spectra of (2*S*,5*S*)-2-Benzyl-5-isobutyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14b**).
- Fig. S-128:** ^1H Spectra of (2*S*,5*S*)-2,5-Dibenzyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14c**).
- Fig. S-129:** ^{13}C Spectra of (2*S*,5*S*)-2,5-Dibenzyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14c**).
- Fig. S-130:** HPLC Spectra of (2*S*,5*S*)-2,5-dibenzyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14c**).
- Fig. S-131:** ^1H Spectra of (2*S*,5*S*)-2,5-dimethyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14d**).
- Fig. S-132:** ^{13}C Spectra of (2*S*,5*S*)-2,5-dimethyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14d**).
- Fig. S-133:** ^1H Spectra of (2*S*,5*S*)-2,5-diisopropyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14e**).
- Fig. S-134:** ^{13}C Spectra of (2*S*,5*S*)-2,5-diisopropyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*][1,4,7]triazonine (**14e**).
- Fig. S-135:** ^1H Spectra of (*S*)-Methyl-2-(*N*-((*S*)-2-(2-(*N*-((*S*)-2-(tert-butoxycarbonylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)-3-methylbutanoate (**16a**).

Fig. S-136: ^{13}C Spectra of (S)-Methyl-2-(N-((S)-2-(2-(N-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)-3-methylbutanoate (**16a**).

Fig. S-137: ^1H Spectra of (S)-Methyl-2-(N-((S)-2-(2-(N-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)-4-methylpentanoate (**16b**).

Fig. S-138: ^{13}C Spectra of (S)-Methyl-2-(N-((S)-2-(2-(N-((S)-2-(tert-butoxycarbonylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)-4-methylpentanoate (**16b**).

Fig. S-139: ^1H Spectra of (S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)butanoate (**18a**).

Fig. S-140: ^{13}C Spectra of (S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)butanoate (**18a**).

Fig. S-141: ^1H Spectra of (S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (**18b**).

Fig. S-142: ^{13}C Spectra of (S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (**18b**).

Fig. S-143: ^1H Spectra of N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**19a**).

Fig. S-144: ^{13}C Spectra of N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)benzenesulfonamide (**19a**).

Fig. S-145: ^1H Spectra of (3S,6S,9S)-3,9-Dibenzyl-6-isopropyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]-tetraazacyclododecine (**20a**).

Fig. S-146: ^{13}C Spectra of (3S,6S,9S)-3,9-Dibenzyl-6-isopropyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]- tetraaza-cyclododecine (**20a**).

Fig. S-147: HPLC Spectra of (3S,6S,9S)-3,9-Dibenzyl-6-isopropyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]- tetraaza-cyclododecine (**20a**).

Fig. S-148: ^1H Spectra of (3S,6S,9S)-3,9-Dibenzyl-6-isobutyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]- tetraaza-cyclododecine (**20b**).

Fig. S-149: ^{13}C Spectra of (3S,6S,9S)-3,9-Dibenzyl-6-isobutyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]- tetraaza-cyclododecine (**20b**).

Fig. S-150: HPLC Spectra of (3S,6S,9S)-3,9-Dibenzyl-6-isobutyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]- tetraaza-cyclododecine (**20b**).

Fig. S-151: ^1H Spectra of (2S,5S,8S)-2,8-Dibenzyl-5-isopropyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]tetraazacyclododecine (**21**).

Fig. S-152: ^{13}C Spectra of (2S,5S,8S)-2,8-Dibenzyl-5-isopropyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]tetraazacyclododecine (**21**).

Fig. S-153: UV-Visible spectra of various cations in solution which have been used. .

Fig. S-154: UV-visible spectra of **14d** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.

Fig. S-155: UV-visible spectra of **14e** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.

Fig. S-156: UV-visible spectra of **14a** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.

Fig. S-157: UV-visible spectra of **14b** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.

Fig. S-158: UV-visible spectra of **14c** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation

Fig. S-159: UV-visible spectra of **14d** with gradual addition of Ni^{2+} solution.

Fig. S-160: UV-visible spectra of **14e** with gradual addition of Ni^{2+} solution.

Fig. S-161: UV-visible spectra of **14a** with gradual addition of Ni^{2+} solution.

Fig. S-162: UV-visible spectra of **21** in acetonitrile.

Fig. S-163: (a)**14d** optimised in PCM mode (Acetonitrile) (b) gaseous phase.


Fig. S-164: Comparisons of Energies, selected bond angles and dihedral angles of **14d** calculated by DFT in PCM mode and gaseous phase.

Fig. S-165: (a)**14c** optimised in PCM mode (Acetonitrile) (b) gaseous phase.


Fig. S-166: Comparisons of Energies, selected bond angles and dihedral angles of **14c** calculated by DFT in PCM mode and gaseous phase.

Fig. S-167: UV Visible spectra of **14d** in different solvents (THF= Tetra hydro furan, MeOH= Methanol, ACN=Acetonitrile, EtoAc= Ethyl acetate).


Fig. S-168: UV Visible spectra of **14c** in different solvents (THF= Tetra hydro furan, MeOH= Methanol, ACN=Acetonitrile, EtoAc= Ethyl acetate)




FigureS-1: ¹H spectrum(300 MHz, CDCl₃) of **3a**




FigureS-2: ¹³C spectrum (75MHz, CDCl₃) of **3a**




FigureS-3: ¹H spectrum(200 MHz, CDCl₃) of **3b**



FigureS-4: ¹³C spectrum (75MHz, CDCl₃) of **3b**





mixture of **3b** and its enantiomer




Retention time (min)


FigureS-5: HPLC spectrum of mixture of **3b** and its enantiomer.




FigureS-6: HPLC spectrum of **3b**.




FigureS- 7: ¹H spectrum (300MHz, CDCl₃) of **3c**.




FigureS -8: ¹³C spectrum (75MHz, CDCl₃) **3c**.




FigureS-9: ¹H spectrum (300MHz, CDCl₃) **3d**.




FigureS-10: ¹³C spectrum (75MHz, CDCl₃) **3d**.




FigureS-11: ¹H spectrum (300MHz, CDCl₃) **3e**.





FigureS-12: ¹³C spectrum (75MHz, CDCl₃) **3e**.



FigureS-13: ¹H spectrum (300MHz, CDCl₃) **3f**.




FigureS-14: ¹³C spectrum (50 MHz, CDCl₃) **3f**.




Retention time (min)


FigureS-15: HPLC spectrum of **3f**.




FigureS-16: ^1H spectrum (300 MHz, CDCl_3) **3g**.




FigureS-17: ¹³C spectrum (75MHz, CDCl₃) **3g**.




FigureS-18: ^1H spectrum (300MHz, CDCl_3) **4a**.




FigureS-19: ¹³C spectrum (75MHz, CDCl₃) **4a**.




FigureS-20: ¹H spectrum (300MHz, CDCl₃) **4b**.




FigureS-21: ¹³C spectrum (50 MHz, CDCl₃) **4b**.




FigureS-22: ¹H spectrum (300MHz, CDCl₃) **4c**.




FigureS-23: ^{13}C spectrum (75MHz, CDCl_3) **4c**.




FigureS-24: ¹H spectrum (300MHz, CDCl₃) **4d**.




FigureS-25: ¹³C spectrum (75MHz, CDCl₃) **4d**.




FigureS-26: ¹H spectrum (300MHz, CDCl₃) **4e**.




FigureS-27: ¹³C spectrum (75MHz, CDCl₃) **4e**.




FigureS-28: ^1H spectrum (300MHz, CDCl_3) **4f**.




FigureS-29: ^{13}C spectrum (75MHz, CDCl_3) of **4f**.




FigureS-30: ¹H spectrum (300MHz, CDCl₃) of **4g**.




FigureS-31: ¹³C spectrum (50 MHz, CDCl₃) of **4g**.




FigureS-32: ¹H spectrum (300MHz, CDCl₃) of 5a.




FigureS-33: ^{13}C spectrum (75MHz, CDCl₃) of **5a**.




FigureS-34: ¹H spectrum (300MHz, CDCl₃) of **5b**.




FigureS-35: ^{13}C spectrum (75MHz, CDCl_3) of **5b**.




FigureS-36: ¹H spectrum (300MHz, CDCl₃) of **5c**.




FigureS-37: ¹³C spectrum (50 MHz, CDCl₃) of **5c**.




FigureS-38: ¹H spectrum (300MHz, CDCl₃) of **5d**.




FigureS-39: ^{13}C spectrum (75MHz, CDCl₃) of **5d**.




FigureS-40: ¹H spectrum (300MHz, CDCl₃) of **5e**.




FigureS-41: ^{13}C spectrum (75MHz, CDCl_3) of **5e**.




FigureS-42: ¹H spectrum (300MHz, CDCl₃) of **5f**.




FigureS-43: ^{13}C spectrum (75MHz, CDCl₃) of **5f**.




FigureS-44: ¹H spectrum (300MHz, CDCl₃) of **5g**.





FigureS-45: ^{13}C spectrum (50 MHz, CDCl_3) of **5g**.



FigureS-46: ¹H spectrum (300MHz, CDCl₃) of **6a**.




FigureS-47 : ¹³C spectrum (75MHz, CDCl₃) of **6a**.




Retention time (min)



FigureS-48: HPLC spectrum of **6a**.




Figures-49: ¹H spectrum (300MHz, CDCl₃) of **6b**.




FigureS-50: ¹³C spectrum (75 MHz, CDCl₃) of **6b**.





FigureS-51: HPLC graph for **6b**



FigureS-52: ¹H spectrum (300MHz, CDCl₃) of **6c**.




FigureS-53: ^{13}C spectrum (75MHz, CDCl_3) of **6c**.




Retention time (min)



FigureS-54: HPLC graph for **6c**




FigureS-55: ¹H spectrum (300MHz, CDCl₃) of **6d**.




FigureS-56: ¹³C spectrum (75MHz, CDCl₃) of **6d**.





FigureS-57: HPLC graph for 6d



FigureS-58: ¹H spectrum (300MHz, CDCl₃) of **6e**.




FigureS-59: ¹³C spectrum (75MHz, CDCl₃) of **6e**.




Retention time (min)



FigureS-60: HPLC graph for **6e**





FigureS-61: ^1H spectrum (300MHz, CDCl_3) of **6f**.




FigureS-62: ¹³C spectrum (75MHz, CDCl₃) of **6f**.




FigureS-63: HPLC graph for mixture of **6f** and its enantiomer.




FigureS-64: HPLC graph for pure **6f**.





FigureS-65: HPLC graph for co-injection of racemic plus **6f**.




FigureS-66: ¹H spectrum (300MHz, CDCl₃) of **6g**.




FigureS-67: ^{13}C spectrum (75MHz, CDCl_3) of **6g**.




FigureS-68: HPLC graph for **6g**




FigureS-69: ¹H spectrum (200MHz, CDCl₃) of **7a**.




FigureS-70: ^{13}C spectrum (50MHz, CDCl_3) of **7a**.




FigureS-71: ¹H spectrum (200MHz, CDCl₃) of **7b**.




FigureS-72: ^{13}C spectrum (50MHz, CDCl_3) of **7b**.




FigureS-73: ¹H spectrum (300MHz, CDCl₃ + CCl₄) **7c**.




FigureS-74: ^{13}C spectrum (50MHz, $\text{CDCl}_3 + \text{CCl}_4$) **7c**.




FigureS-75: ¹H spectrum (200MHz, CDCl₃) of **8a**.





FigureS-76: ¹³C spectrum (75 MHz, CDCl₃) of **8a**.



FigureS-77: ¹H spectrum (300MHz, CDCl₃) of **8b**




FigureS-78: ^{13}C spectrum (50 MHz, CDCl_3) of **8b**.




Retention time (min)


FigureS-79: HPLC graph for **8b**.




FigureS-80: ¹H spectrum (300MHz, CDCl₃) of **10a**.




FigureS-81: ¹³C spectrum (75MHz, CDCl₃) of **10a**.




FigureS-82: ^1H spectrum (300MHz, CDCl_3) of **10b**.




FigureS-83: ^{13}C spectrum (75MHz, CDCl_3) of **10b**.




FigureS-84: ¹H spectrum (300MHz, CDCl₃) of **10c**.




FigureS-85: ¹³C spectrum (75MHz, CDCl₃) of **10c**.




FigureS-86: ¹H spectrum (300MHz, CDCl₃) of **10d**.




FigureS-87: ¹³C spectrum (75MHz, CDCl₃) of **10d**.




FigureS-88: ^1H spectrum (300MHz, CDCl_3) of **10e**.




FigureS-89: ^{13}C spectrum (75MHz, CDCl_3) of **10e**.




FigureS-90: ¹H spectrum (300MHz, CDCl₃) of **10f**.




FigureS-91: ^{13}C spectrum (75MHz, CDCl_3) of **10f**.




FigureS-92: ¹H spectrum (300MHz, CDCl₃) of **11a**.




FigureS-93: ^{13}C spectrum (75MHz, CDCl_3) of **11a**.




FigureS-94: ¹H spectrum (300MHz, CDCl₃) of **11b**.



FigureS-95: ¹³C spectrum (75MHz, CDCl₃) of **11b**.




FigureS-96: ¹H spectrum (300MHz, CDCl₃) of **11c**.




FigureS-97: ^{13}C spectrum (75MHz, CDCl_3) of **11c**.


110




FigureS-99: ^{13}C spectrum (75 MHz, CDCl_3) of **11d**.




FigureS-100: ^1H spectrum (300MHz, CDCl_3) of **12b**.




FigureS-101: ¹³C spectrum (75 MHz, CDCl₃) of **12b**.




FigureS-102: ^1H spectrum (300MHz, CDCl_3) of **12c**.




FigureS-103: ¹H spectrum (300MHz, CDCl₃) of **12d**.




FigureS-105: ¹H spectrum (300MHz, CDCl₃) of **12e**.




FigureS-106: ^{13}C spectrum (75 MHz, CDCl_3) of **12e**.




FigureS-107: ^1H spectrum (300MHz, CDCl_3) of **12f**.





FigureS-108: ^{13}C spectrum (75 MHz, CDCl_3) of **12f**.




FigureS-109: ^1H spectrum (300MHz, CDCl_3) of **13a**.



FigureS-110: ^{13}C spectrum (75MHz, CDCl_3) of **13a**.



FigureS-111: HPLC graph for **13a**



FigureS-112: ¹H spectrum (300MHz, CDCl₃) of **13b**.









Figure S-113: ^{13}C spectrum (75MHz, CDCl_3) of **13b**.





FigureS-114: HPLC graph for mixture of **13b** and its enantiomer.




FigureS-115: HPLC graph for enantiomerically pure **13b**.




FigureS-117: ^{13}C spectrum (75MHz, CDCl_3) of **13c**.





FigureS-118: HPLC graph for 13c




FigureS-119: ^1H spectrum (300MHz, CDCl_3) of **13d**.




FigureS-120: ^{13}C spectrum (75MHz, CDCl_3) of **13d**.




FigureS-121: HPLC graph for **13d**.




FigureS-122: ^1H spectrum (300MHz, CDCl_3) of **13e**.




FigureS-123: ^{13}C spectrum (50MHz, CDCl_3) of **13e**.




FigureS-124: ^1H spectrum (200MHz, CDCl_3) of **13f**




FigureS-125: ^{13}C spectrum (50MHz, CDCl_3) of **13e**.




FigureS-126: ¹H spectrum (300MHz, CDCl₃) of **14a**.





FigureS-127: ¹H spectrum (300MHz, CDCl₃) of **14b**.




FigureS-128: ^1H spectrum (300MHz, CDCl_3) of **14c**.




FigureS-129: ^{13}C spectrum (75MHz, CDCl_3) of **14c**.




FigureS-130: HPLC graph for **14c**.




FigureS-131: ¹H spectrum (300MHz, CDCl₃) of **14d**.




FigureS-132: ¹³C spectrum (75MHz, CDCl₃) of **14d**.




FigureS-133: ¹H spectrum (300MHz, CDCl₃) of **14e**.




FigureS-134: ¹³C spectrum (75MHz, CDCl₃) of **14e**.




FigureS-135: ^1H spectrum (300MHz, CDCl_3) of **16a**.




FigureS-136: ¹³C spectrum (75 MHz, CDCl₃) of **16a**.



FigureS-137: ^1H spectrum (300MHz, CDCl_3) of **16b**.




FigureS-138: ^{13}C spectrum (75 MHz, CDCl_3) of **16b**.




151


FigureS-139: ^1H spectrum (300MHz, CDCl_3) of **18a**.




FigureS-140: ¹³C spectrum (75 MHz, CDCl₃) of **18a**.




FigureS-141: ¹H spectrum (300 MHz, CDCl₃) of **18b**.




FigureS-142: ^{13}C spectrum (75 MHz, CDCl_3) of **18b**.




FigureS-143: ¹H spectrum (300MHz, CDCl₃) of **19a**.





FigureS-144: ^{13}C spectrum (75MHz, CDCl_3) of **19a**.




FigureS-145: ^1H spectrum (300MHz, CDCl_3) of **20a**.




FigureS-146: ^{13}C spectrum (75 MHz, CDCl_3) of **20a**.





FigureS-147: HPLC graph for **20a**



FigureS-148: ¹H spectrum (300MHz, CDCl₃) of **20b**.




FigureS-149: ^{13}C spectrum (75MHz, CDCl_3) of **20b**.




Retention time (min)

FigureS-150: HPLC graph for **20b**



FigureS-151: ¹H spectrum (300MHz, CDCl₃) of **21**.



FigureS-152: ¹³C spectrum (75MHz, CDCl₃) of **21**.




Fig. S-153: UV-Visible spectra of various cations in solution which have been used.




Fig. S-154: UV-visible spectra of **14d** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.




Fig. S-155: UV-visible spectra of **14e** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.




Fig. S-156: UV-visible spectra of **14a** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition of the same cation.




Fig. S-157: UV-visible spectra of **14b** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition the same cation.




Fig. S-158: UV-visible spectra of **14c** with gradual addition of Co^{2+} solution. Figure depicts the different kinds of response on addition of the same cation.




Fig. S-159: UV-visible spectra of **14d** with gradual addition of Ni^{2+} solution.




Fig. S-160: UV-visible spectra of **14e** with gradual addition of Ni^{2+} solution.




Fig. S-161: UV-visible spectra of **14a** with gradual addition of Ni^{2+} solution.




Fig. S-162: UV-visible spectra of **21** in acetonitrile.




Fig. S-163: (a) **14d** optimised in PCM mode (Acetonitrile) (b) gaseous phase.

	Polarizable Continuum Model(PCM) opt b3lyp/6-31++g(d,p) scrf=(solvent=acetonitrile)	gas phase opt b3lyp/6-31++g(d,p)
Energy	-397223.99 kcal/mol	-397212.88 kcal/mol
Di hedral angle C3-C4-C5-N11	-174.34⁰	-175.03⁰
C2-C1-C6-N13	172.86⁰	173.21⁰
C6-N13-C18-C25	-90.67⁰	-89.80⁰
N13-C18-C20-N33	-79.07⁰	-76.93⁰
N11-C15-C23-N33	135.28⁰	135.34⁰
C18-C20-N33-C23	60.38⁰	60.4⁰
C15-C23-N33-C20	-90.56⁰	-89.80⁰
C25-C18-C20-N33	156.78⁰	158.53⁰
N11-C15-C23-C29	-103.2⁰	-103.28⁰
C3-C4-C5-N11	-174.34⁰	-175.03⁰
C2-C1-C6-N13	172.86⁰	173.21⁰
C5-N11-C15-C23	-104.63⁰	-103.28⁰
Bond Angle C6-N13-C18	120.11⁰	120.91⁰
C5-N11-C15	121.92⁰	122.44⁰
N13-C18-C25	112.21⁰	112.59⁰
C25-C18-C20	110.65⁰	110.85⁰
C20-N33-C23	116.06⁰	116.95⁰
N33-C23-C15	109.66⁰	109.36⁰
C29-C23-C15	111.09⁰	111.24⁰
C23-C15-N11	115.80⁰	115.58⁰

Fig. S-164: Comparisons of Energies, selected bond angles and dihedral angles of **14d** calculated by DFT in PCM mode and gaseous phase.




Fig. S-165: (a) **14c** optimised in PCM mode (Acetonitrile) (b) gaseous phase.

	Polarizable Continuum Model(PCM)opt b3lyp/6-31++g(d,p) scrf=(solvent=acetonitrile)	gas phase opt b3lyp/6-31++g(d,p)
Energy	-687219.46 kcal/mol	-687203.58 kcal/mol
Di hedral angle C3-C4-C5-N11	-173.96⁰	-174.66⁰
C2-C1-C6-N13	173.27⁰	173.20⁰
C4-5C-N11-15C	-134.90⁰	-135.81⁰
C1-C6-N13-C18	91.28⁰	88.86⁰
N11-C15-C23-N31	135.91⁰	135.78⁰
N11-C15-C23-C28	-102.3⁰	-102.8⁰
C6-N13-C18-C20	146.23⁰	147.34⁰
C5-N11-C15-C23	-103.38⁰	-102.70⁰
C15-C23-C28-C44	171.68⁰	174.1⁰
C20-C18-C25-C33	-65.84⁰	-66.72⁰
N13-C18-C20-N31	-79.09⁰	-76.79⁰
C44-C28-C20-N31	-66.92⁰	-64.89⁰
C15-C23-N31-C20	-91.02⁰	-91.12⁰
C1-C6-N13-C18	91.28⁰	88.86⁰
C4-C5-N11-C15	-134.98⁰	-135.81⁰
C18-C25-C33-C34	109.50⁰	108⁰
C18-C25-C33-C35	-70.73⁰	-71.95⁰
Bond Angle C6-N13-C18	120.35⁰	120.16⁰
C5-N11-C15	122.14⁰	122.62⁰
C18-C25-C33	115.03	115.03
N13-C18-C20	109.3⁰	108.92⁰
C20-N31-C23	115.89⁰	116.96⁰
N11-C15-C23	115.64⁰	115.6⁰
C15-C23-N31	109.56⁰	109.5⁰
C23-C28-C44	114.65⁰	114.52⁰
C28-C23-N31	110.66⁰	110.18⁰
C28-C23-C15	110.27	110.27

Fig. S-166: Comparisons of Energies, selected bond angles and dihedral angles of **14c** calculated by DFT in PCM mode and gaseous phase.




Fig. S-167: UV Visible spectra of **14d** in different solvents (THF= Tetra hydro furan, MeOH= Methanol, ACN=Acetonitrile, EtOAc= Ethyl acetate)




Fig. S-168: UV Visible spectra of **14c** in different solvents (THF= Tetra hydro furan, MeOH= Methanol, ACN=Acetonitrile, EtOAc= Ethyl acetate)

(2S)-2-(2-Nitrophenylamino)-3-phenylpropionic Acid Methyl Ester (3b). Yellow oil; yield, 65% (based on two steps); $R_f = 0.53$ (8.5/1.5, hexane/EtOAc); HPLC analysis: ee > 99 ($t_R = 19.7$ min, hexane/propanol); IR $\nu_{\max}$ (neat, cm^{-1}) 3451, 2927, 2857, 2372, 1744, 1619, 1511, 1269, 750; ^1H NMR (200 MHz, CDCl_3) δ 8.17 (d, 1H, $J = 1.6$), 8.13 (d, 1H), 7.38-7.20 (m, 6H), 6.71-6.64 (m, 2H), 4.48-4.45 (m, 1H), 3.72 (s, 3H), 3.28-3.20 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 171.9, 143.7, 136.1, 135.4, 132.6, 129.0, 128.7, 127.3, 126.8, 116.3, 113.6, 57.2, 52.4, 38.5; MS (ESI): m/z 301 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{16}\text{H}_{16}\text{N}_2\text{O}_4$: C 63.99; H, 5.37; N, 9.33; Found: C, 63.91; H, 5.41; N, 9.39.

(2S)-4-Methyl-2-(2-nitrophenylamino)pentanoic Acid Methyl Ester (3c). Yellow oil; yield, 64% (based on two steps); $R_f = 0.53$ (8.5/1.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3448, 2935, 2856, 2356, 1743, 1620, 1511, 1268, 748; ^1H NMR (300 MHz, CDCl_3) δ 8.21 (d, 1H, $J = 1.6$), 8.18 (d, 1H, $J = 1.6$), 7.47-7.42 (m, 1H), 6.76-6.69 (m, 2H), 4.29-4.22 (m, 1H), 3.76 (s, 3H), 1.85-1.82 (m, 3H), 1.03 (d, 3H, $J = 6.3$), 0.96 (d, 3H, $J = 6.3$); ^{13}C NMR (75 MHz, CDCl_3) δ 173.2, 144.2, 136.3, 132.6, 127.0, 116.2, 113.6, 54.5, 52.4, 41.6, 24.9, 22.7, 21.9; MS (ESI): m/z 267 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_4$: C, 58.63; H, 6.81; N, 10.52; Found: C, 58.67; H, 6.84; N, 10.55.

(2S,3S)-Methyl-3-methyl-2-(2-nitrophenylamino)pentanoic Acid Methyl Ester (3d). Yellow oil; yield, 66% (based on two steps); $R_f = 0.56$ (8.5/1.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3451, 2625, 2856, 1744, 1619, 1265, 744; ^1H NMR (300 MHz, CDCl_3) δ 8.42 (d, 1H), 8.21 (dd, 1H, $J_1 = 1.5$, $J_2 = 8.5$), 7.47-7.41 (m, 1H), 6.77-6.68 (m, 2H), 4.17-4.13 (m, 1H), 3.77 (s, 3H), 2.12-2.03 (m, 1H), 1.71-1.62 (m, 1H), 1.45-1.35 (m, 1H), 1.05 (d, 3H, $J = 6.9$), 1.00 (t, 3H, $J = 7.3$); ^{13}C NMR (75 MHz, CDCl_3) δ 172.1, 144.4, 136.3, 132.6, 127.0, 116.1, 113.6, 60.5, 52.2, 37.8, 25.5, 15.6, 11.4; MS (ESI): m/z 267 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{13}\text{H}_{18}\text{N}_2\text{O}_4$: C, 58.63; H, 6.81; N, 10.52; Found: C, 58.61, H, 6.88; N, 10.56.

(2S)-3-(1*H*-Indol-3-yl)-2-(2-nitrophenylamino)propionic Acid Methyl Ester (3e). Yellow oil; yield, 63% (based on two steps); R_f = 0.45 (8.5/1.5, hexane/EtOAc); HPLC analysis: ee > 99 (t_R = 12.9 min, hexane/propanol); IR $\nu_{\max}$ (neat, cm^{-1}) 3448, 2984, 2368, 1744, 1642, 1460, 1296, 751; ^1H NMR (300 MHz, CDCl_3) δ 8.43 (d, 1H, J = 6.9), 8.24 (bs, 1H), 8.16 (dd, 1H, J_1 = 1.6, J_2 = 8.9), 7.60 (d, 1H, J = 7.7), 7.40-7.34 (m, 2H), 7.24-7.12 (m, 3H), 6.70-6.65 (m, 2H), 4.61-4.55 (m, 1H), 3.72 (s, 3H), 3.55-3.40 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.6, 144.0, 136.25, 136.17, 132.6, 127.0, 126.9, 123.5, 122.3, 119.6, 118.2, 116.2, 113.8, 111.4, 109.3, 56.2, 52.5, 28.6; MS (ESI): m/z 340 [$\text{M} + \text{H}$] $^+$; Anal. calcd. (%) for $\text{C}_{18}\text{H}_{17}\text{N}_3\text{O}_4$: C, 63.71; H, 5.05; N, 12.38; Found: C, 63.68; H, 5.13; N, 12.43.

(2S)-4-Methylsulfanyl-2-(2-nitrophenylamino)butyric Acid Methyl Ester (3g). Yellow oil; yield, 69% (based on two steps); R_f = 0.54 (8.5/1.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3397, 2967, 2366, 1743, 1620, 1512, 1160, 747; ^1H NMR (300 MHz, CDCl_3) δ 8.30 (d, 1H, J = 7.8), 8.19 (dd, 1H, J_1 = 1.6, J_2 = 8.6), 7.47-7.42 (m, 1H), 6.82 (d, 1H, J = 8.4), 6.75-6.70 (m, 1H), 4.54-4.47 (m, 1H), 3.78 (s, 3H), 2.68-2.60 (m, 2H), 2.30-2.16 (m, 2H), 2.11 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 172.2, 144.0, 136.2, 132.8, 126.9, 116.4, 113.7, 54.3, 52.6, 31.7, 30.0, 15.4; MS (ESI): m/z 285 [$\text{M} + \text{H}$] $^+$; Anal. calcd. (%) for $\text{C}_{12}\text{H}_{16}\text{N}_2\text{O}_4\text{S}$: C, 50.69; H, 5.67; N, 9.85; Found: C, 50.74; H, 5.64; N, 9.89.

(2S)-2-(2-Aminophenylamino)-4-methylpentan-1-ol (4c). Brown oil; yield, 38%; R_f = 0.52 (6.5/3.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3651, 3451, 2926, 2369, 1653, 1628, 1380, 760; ^1H NMR (300 MHz, CDCl_3) δ 6.86-6.80 (m, 1H), 6.75-6.67 (m, 3H), 3.80-3.76 (m, 1H), 3.57-3.47 (m, 2H), 1.80-1.71 (m, 1H), 1.56-1.37 (m, 2H), 0.98 (d, 3H, J = 6.5), 0.92 (d, 3H, J = 6.5); ^{13}C NMR (75 MHz, CDCl_3) δ 136.9, 134.3, 120.9, 118.9, 117.4, 113.1, 64.2, 52.9, 41.4, 24.9, 22.8, 22.8; MS (ESI): m/z 209 [$\text{M} + \text{H}$] $^+$; Anal. calcd. (%) for $\text{C}_{12}\text{H}_{20}\text{N}_2\text{O}$: C, 69.19; H, 9.68; N, 13.45; Found: C, 69.24; H, 9.65; N, 13.52.

(2S,3S)-2-(2-Aminophenylamino)-3-methylpentan-1-ol (4d). Brown oil; yield, 35%; $R_f = 0.50$ (6.5/3.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3654, 3450, 2925, 2369, 1628, 1380, 760; ^1H NMR (300 MHz, CDCl_3) δ 6.87-6.81 (m, 1H), 6.78-6.67 (m, 3H), 3.80 (dd, 1H, $J_1 = 3.9$, $J_2 = 11.2$), 3.59 (dd, 1H, $J_1 = 6.9$, $J_2 = 11.2$), 3.44-3.38 (m, 1H), 1.77-1.70 (m, 1H), 1.64-1.56 (m, 1H), 1.33-1.19 (m, 1H), 0.95 (d, 3H, $J = 6.8$), 0.94 (t, 3H, $J = 7.3$); ^{13}C NMR (75 MHz, CDCl_3) δ 137.4, 134.2, 121.0, 118.7, 117.6, 113.2, 61.5, 58.9, 36.0, 26.2, 14.9, 11.8; MS (ESI): m/z 209 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{12}\text{H}_{20}\text{N}_2\text{O}$: C, 69.19; H, 9.68; N, 13.45; Found: C, 69.28; H, 9.63; N, 13.40.

(2S)-2-(2-Aminophenylamino)-3-(1H-Indol-3-yl)-propan-1-ol (4e). Brown oil; yield, 24%; $R_f = 0.45$ (6.5/3.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3652, 3438, 2926, 1600, 1458, 1163, 750; ^1H NMR (300 MHz, CDCl_3) δ 8.12 (bs, 1H), 7.62 (d, 1H, $J = 7.7$), 7.34 (d, 1H, $J = 8.0$), 7.23-7.11 (m, 2H), 6.97 (d, 1H, $J = 1.8$), 6.87-6.71 (m, 4H), 3.85-3.74 (m, 2H), 3.60-3.55 (m, 1H), 3.15-3.06 (m, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 136.2, 135.2, 127.7, 122.7, 122.1, 120.7, 119.5, 118.7, 117.1, 113.9, 111.9, 111.2, 63.5, 55.1, 26.9; MS (ESI): m/z 282 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}$: C, 72.57; H, 6.81; N, 14.94; Found: C, 72.52; H, 6.85; N, 14.98.

(2S)-2-(2-Aminophenylamino)-3-methylbutan-1-ol (4f). Brown oil; yield, 42%; $R_f = 0.53$ (6.5/3.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3654, 3425, 2927, 2341, 1652, 1460, 760; ^1H NMR (300 MHz, CDCl_3) δ 6.86-6.80 (m, 1H), 6.72-6.66 (m, 3H), 3.78 (dd, 1H, $J_1 = 4.0$, $J_2 = 11.1$), 3.58 (dd, 1H, $J_1 = 6.5$, $J_2 = 11.1$), 3.33-3.27 (m, 1H), 3.06 (bs, 4H), 2.02-1.90 (m, 1H), 1.03 (d, 3H, $J = 7.0$), 0.98 (d, 3H, $J = 7.0$); ^{13}C NMR (75 MHz, CDCl_3) δ 137.5, 134.2, 121.0, 118.7, 117.6, 113.3, 62.0, 60.4, 29.6, 19.3, 18.8; MS (ESI): m/z 195 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{11}\text{H}_{18}\text{N}_2\text{O}$: C, 68.01; H, 9.34; N, 14.42; Found: C, 68.10; H, 9.38; N, 14.45.

(2S)-2-(2-Aminophenylamino)-4-methylsulfanylbutan-1-ol (4g). Brown oil; yield, 23%; $R_f = 0.52$ (6.5/3.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3651, 3422, 2926, 2341, 1658, 1461, 758; ^1H NMR (300 MHz, CDCl_3) δ 6.85-6.80 (m, 1H), 6.75-6.67 (m, 3H), 3.76 (dd, 1H, $J_1 = 3.6$, $J_2 = 10.8$), 3.66-3.52 (m, 2H), 3.14 (bs, 4H), 2.64-2.52 (m, 2H), 2.11 (s, 3H), 1.92-1.85 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3) δ 137.0, 134.9, 121.4, 119.6, 117.9, 114.0, 64.0, 54.2, 31.6, 31.4, 16.0; MS (ESI): m/z 227 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{11}\text{H}_{18}\text{N}_2\text{OS}$: C, 58.37; H, 8.02; N, 12.38; Found: C, 58.40; H, 8.11; N, 12.43.

(S)-N-[2-(1-Hydroxymethyl-2-phenylethylamino)phenyl]-4-methylbenzenesulfonamide (5b). Brown oil; yield, 76%; $R_f = 0.53$ (6.0/4.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3653, 3422, 2926, 2859, 1600, 1485, 1158, 748; ^1H NMR (300 MHz, CDCl_3) δ 7.64-7.62 (m, 2H), 7.30-7.23 (m, 7H), 7.12-7.07 (m, 1H), 6.70 (d, 1H, $J = 8.2$), 6.52 (m, 1H), 6.44-6.43 (m, 2H), 4.72 (m, 1H), 3.77-3.74 (m, 2H), 3.51-3.46 (m, 1H), 2.92-2.77 (m, 3H), 2.43 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 145.1, 144.0, 138.4, 135.5, 129.6, 129.3, 129.2, 128.8, 128.4, 127.6, 126.3, 120.7, 116.7, 112.7, 62.6, 56.1, 37.6, 21.5; MS (ESI): m/z 397 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{22}\text{H}_{24}\text{N}_2\text{O}_3\text{S}$: C, 66.64; H, 6.10; N, 7.07; Found: C, 66.68; H, 6.17; N, 7.12.

(S)-N-[2-(1-Hydroxymethyl-3-methyl-butylamino)phenyl]-4-methylbenzene- sulfonamide (5c). Brown oil; yield, 75 %; $R_f = 0.52$ (6.0/4.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3658, 3431, 2924, 1634, 1159, 746; ^1H NMR (300 MHz, CDCl_3) δ 7.63-7.60 (m, 2H), 7.27-7.25 (m, 2H), 7.12-7.07 (m, 1H), 6.73 (d, 1H, $J = 8.26$), 6.50 (bs, 1H), 6.40-6.39 (m, 2H), 4.50 (bs, 1H), 3.81 (dd, 1H, $J_1 = 3.8$, $J_2 = 11.4$), 3.60 (bs, 1H), 3.47 (dd, 1H, $J_1 = 5.0$, $J_2 = 11.4$), 2.82 (bs, 1H), 2.43 (s, 3H), 1.79-1.65 (m, 1H), 1.47-1.32 (m, 2H), 0.95 (d, 3H, $J = 6.5$), 0.91 (d, 3H, $J = 6.5$); ^{13}C NMR (50 MHz, CDCl_3) δ 146.2, 144.4, 136.0, 130.0, 129.9, 129.4, 128.1, 120.7, 116.6, 112.8, 64.6, 52.9, 41.3, 25.1, 23.3, 23.0, 22.0; MS (ESI): m/z 363 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_3\text{S}$: C, 62.95; H, 7.23; N, 7.73; Found: C, 62.90; H, 7.28; N, 7.75.

N-(2-((2S,3S)-1-Hydroxy-3-methylpentan-2-ylamino)phenyl)-4-methylbenzene- sulfonamide (5d).

Brown oil; yield, 76%; $R_f = 0.53$ (6.0/4.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3654, 3433, 2926, 1437, 1159, 746; ^1H NMR (300 MHz, CDCl_3) δ 7.64-7.62 (m, 2H), 7.28-7.25 (m, 2H), 7.12-7.06 (m, 1H), 6.70 (d, 1H, $J = 8.2$), 6.50 (bs, 1H), 6.38-6.35 (m, 2H), 4.68 (bs, 1H), 3.81 (dd, 1H, $J_1 = 3.1$, $J_2 = 11.6$), 3.61 (dd, 1H, $J_1 = 6.5$, $J_2 = 11.6$), 3.39 (bs, 1H), 2.86 (bs, 1H), 2.43 (s, 3H), 1.71-1.55 (m, 2H), 1.27-1.17 (m, 1H), 0.96 (d, 3H, $J = 6.6$), 0.92 (t, 3H, $J = 7.34$); ^{13}C NMR (75 MHz, CDCl_3) δ 146.3, 144.0, 135.4, 129.5, 129.4, 128.9, 127.7, 120.0, 115.9, 112.2, 62.2, 59.0, 36.4, 25.9, 21.5, 15.3, 11.5; MS (ESI): m/z 363 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{19}\text{H}_{26}\text{N}_2\text{O}_3\text{S}$: C, 62.95; H, 7.23; N, 7.73; Found: C, 62.92; H, 7.27; N, 7.78.

(S)-N-{2-[1-Hydroxymethyl-2-(1*H*-indol-3-yl)-ethylamino] phenyl}-4-methylbenzenesulfonamide

(5e): Brown oil; yield, 72%; $R_f = 0.50$ (6.0/4.0, hexane/ethylacetate); IR $\nu_{\max}$ (neat, cm^{-1}) 3654, 3445, 2928, 1631, 1158, 746; ^1H NMR (300 MHz, CDCl_3) δ 8.13 (bs, 1H), 7.65-7.56 (m, 3H), 7.38 (d, 1H, $J = 8.0$), 7.25-7.08 (m, 6H), 6.75 (d, 1H, $J = 8.2$), 6.46-6.45 (m, 2H), 6.08 (bs, 1H), 4.67 (bs, 1H), 3.86 (bs, 1H), 3.76-3.72 (bs, 1H), 3.52-3.49 (bs, 1H), 3.06-3.04 (m, 2H), 2.41 (s, 4H); ^{13}C NMR (75 MHz, CDCl_3) δ 136.22, 136.17, 135.0, 127.8, 122.7, 122.1, 120.8, 119.5, 119.5, 118.7, 117.2, 114.1, 111.9, 111.2, 63.4, 55.2, 26.9; MS (ESI): m/z 436 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{24}\text{H}_{25}\text{N}_3\text{O}_3\text{S}$: C, 66.18; H, 5.79; N, 9.65; Found: C, 66.25; H, 5.82; N, 9.70.

(S)-N-[2-(1-Hydroxymethyl-2-methylpropylamino)phenyl]-4-methylbenzenesulfonamide (5f).

Brown oil; yield, 73%; $R_f = 0.55$ (6.0/4.0, hexane/ethylacetate); IR $\nu_{\max}$ (neat, cm^{-1}) 3653, 3418, 2926, 1600, 1159, 751; ^1H NMR (300 MHz, CDCl_3) δ 7.64-7.61 (m, 2H), 7.29-7.26 (m, 2H), 7.12-7.06 (m, 1H), 6.72 (d, 1H, $J = 8.1$), 6.39-6.29 (m, 2H), 6.24 (bs, 1H), 4.66 (bs, 1H), 3.82-3.78 (m, 1H), 3.63-3.57 (m, 1H), 3.31 (bs, 1H), 2.76 (bs, 1H), 2.44 (s, 3H), 1.95-1.84 (m, 1H), 1.01 (d, 3H, $J = 6.9$), 0.99 (d, 3H, $J = 6.7$); ^{13}C NMR (75 MHz, CDCl_3) δ 146.6, 144.1, 135.3, 129.5, 128.9, 127.7, 119.8, 115.8, 112.3, 62.5, 60.5, 30.0, 21.5, 19.4, 19.3; MS (ESI): m/z 349 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_3\text{S}$: C, 62.04; H, 6.94; N, 8.04; Found: C, 62.10; H, 6.98; N, 8.10;

(S)-N-[2-(1-Hydroxymethyl-3-methylsulfanylpropylaminophenyl)]-4-methylbenzenesulfonamide

(5g). Brown oil; yield, 75%; $R_f = 0.54$ (6.0/4.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3654, 3420, 2926, 1602, 1325, 1162, 751; ^1H NMR (300 MHz, CDCl_3) δ 7.64-7.61 (m, 2H), 7.29-7.26 (m, 2H), 7.14-7.09 (m, 1H), 6.74 (d, 1H, $J = 6.7$), 6.50 (bs, 1H), 6.47-6.34 (m, 2H), 3.84-3.75 (m, 2H), 3.56-3.51 (m, 1H), 2.64-2.58 (m, 2H), 2.44 (s, 3H), 2.11 (s, 3H), 1.89-1.83 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3) δ 146.2, 144.5, 135.8, 130.03, 129.97, 129.4, 128.1, 120.7, 116.9, 113.1, 64.3, 53.8, 31.5, 31.3, 22.0, 15.9; MS (ESI): m/z 381 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{18}\text{H}_{24}\text{N}_2\text{O}_3\text{S}_2$: C, 56.81; H, 6.36; N, 7.36; Found: C, 56.85; H, 6.43; N, 7.41.

(3S)-3-Isobutyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (6c). Light yellow oil; yield, 75%; overall yield, 13.7%; $R_f = 0.56$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} -58.2$ (c 0.11, MeOH), HPLC analysis: ee > 99 ($t_R = 8.5$ min, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$); IR $\nu_{\max}$ (neat, cm^{-1}) 3395, 2962, 1601, 1495, 1342, 748; ^1H NMR (300 MHz, CDCl_3) δ 7.69 (dd, 1H, $J_1 = 1.2$, $J_2 = 8.2$), 7.48-7.45 (m, 2H), 7.21-7.19 (m, 2H), 7.01-6.96 (m, 1H), 6.73-6.67 (m, 1H), 6.48 (dd, 1H, $J_1 = 1.1$, $J_2 = 8.0$), 4.23 (dd, 1H, $J_1 = 3.1$, $J_2 = 13.9$), 3.66 (bs, 1H), 2.88 (dd, 1H, $J_1 = 10.3$, $J_2 = 13.8$), 2.70-2.67 (m, 1H), 2.38 (s, 3H), 1.63-1.57 (m, 1H), 1.19-1.14 (m, 2H), 0.87 (d, 3H, $J = 6.5$), 0.80 (d, 3H, $J = 6.5$); ^{13}C NMR (75 MHz, CDCl_3) δ 143.6, 137.7, 136.5, 129.5, 127.3, 126.3, 125.8, 121.9, 117.1, 114.6, 49.3, 45.5, 42.9, 24.2, 22.9, 22.2, 21.4; MS (ESI): m/z 345 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{19}\text{H}_{24}\text{N}_2\text{O}_2\text{S}$: C, 66.25; H, 7.02; N, 8.13; Found: C, 66.29; H, 7.10; N, 8.11.

(3S,4S)-3-Secbutyl-1-tosyl-1,2,3,4-Tetrahydroquinoxaline (6d). Yellow semi-solid; yield, 74%; overall yield, 13.0%; $R_f = 0.54$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} +35.7$ (c 0.11, MeOH), HPLC analysis: ee > 99 ($t_R = 12.3$ min, CH₃CN/H₂O); IR $\nu_{\max}$ (KBr, cm⁻¹) 3399, 2964, 1603, 1497, 1346, 750; ¹H NMR (300 MHz, CDCl₃) δ 7.69 (dd, 1H, $J_1 = 1.3$, $J_2 = 8.2$), 7.49-7.47 (m, 2H), 7.23-7.20 (m, 2H), 7.02-6.96 (m, 1H), 6.73-6.67 (m, 1H), 6.50 (dd, 1H, $J_1 = 1.3$, $J_2 = 8.0$), 4.26 (dd, 1H, $J_1 = 3.0$, $J_2 = 13.9$), 3.67 (bs, 1H), 3.00 (dd, 1H, $J_1 = 10.4$, $J_2 = 14.0$), 2.59-2.57 (m, 1H), 2.40 (s, 3H), 1.41-1.19 (m, 3H), 0.88 (d, 3H, $J = 6.7$), 0.86 (t, 3H, $J = 7.4$); ¹³C NMR (75 MHz, CDCl₃) δ 143.5, 138.2, 136.6, 129.5, 127.3, 126.3, 125.7, 122.0, 117.0, 114.6, 51.1, 46.1, 37.6, 25.2, 21.5, 13.9, 11.1; MS (ESI): m/z 345 [M + H]⁺; Anal. calcd. (%) for C₁₉H₂₄N₂O₂S: C, 66.25; H, 7.02; N, 8.13; Found: C, 66.29; H, 7.06; N, 8.19.

(3S)-3-(1H-Indol-3-ylmethyl)-1-tosyl-1,2,3,4-tetrahydroquinoxaline (6e). Yellow, solid; mp 172-174 °C; yield, 72%; overall yield, 7.8%; $R_f = 0.50$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} -53.1$ (c 0.11, MeOH), HPLC analysis: ee > 99 ($t_R = 11.9$ min, CH₃CN/H₂O); IR $\nu_{\max}$ (KBr, cm⁻¹) 3373, 2923, 1704, 1343, 1235, 1163, 750; ¹H NMR (300 MHz, CDCl₃) δ 8.15 (bs, 1H), 7.72 (dd, 1H, $J_1 = 1.3$, $J_2 = 8.3$), 7.42-7.37 (m, 3H), 7.33-7.22 (m, 2H), 7.15-7.09 (m, 3H), 7.02 (d, 1H, $J = 2.1$), 6.98-6.92 (m, 1H), 6.73-6.66 (m, 1H), 6.37 (dd, 1H, $J_1 = 1.3$, $J_2 = 8.0$), 4.34-4.33 (m, 1H), 3.78 (bs, 1H), 3.09 (dd, 1H, $J_1 = 10.4$, $J_2 = 13.8$), 3.01-2.84 (m, 2H), 2.60 (dd, 1H, $J_1 = 8.5$, $J_2 = 13.8$), 2.35 (s, 3H); ¹³C NMR (75 MHz, CDCl₃) δ 143.6, 137.8, 136.6, 135.9, 129.6, 127.1, 126.9, 126.3, 125.7, 123.1, 122.0, 121.6, 119.1, 118.5, 117.0, 114.6, 111.4, 50.3, 46.6, 29.8, 21.4; MS (ESI): m/z 418 [M + H]⁺; Anal. calcd. (%) for C₂₄H₂₃N₃O₂S: C, 69.04; H, 5.55; N, 10.06; Found: C, 69.10; H, 5.63; 10.13.

(3S)-3-Isopropyl-1-tosyl-1,2,3,4-tetrahydroquinoxaline (6f). Yellow, semi-solid; yield, 75%; overall yield, 15.6%; $R_f = 0.54$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} -45.9$ (c 0.12, MeOH), HPLC analysis: ee > 99 ($t_R = 32.5$ min, hexane/propanol); IR $\nu_{\max}$ (KBr, cm^{-1}) 3404, 2962, 1602, 1499, 1346, 1162, 751; ^1H NMR (300 MHz, CDCl_3) δ 7.68 (dd, 1H, $J_1 = 1.0$, $J_2 = 8.2$), 7.49-7.46 (m, 2H), 7.22-7.19 (m, 2H), 7.01-6.95 (m, 1H), 6.71-6.66 (m, 1H), 6.51 (dd, 1H, $J_1 = 0.9$, $J_2 = 8.1$), 4.27 (dd, 1H, $J_1 = 3.2$, $J_2 = 13.9$), 3.7 (bs, 1H), 3.00 (dd, 1H, $J_1 = 10.4$, $J_2 = 13.9$), 2.46-2.42 (m, 1H), 2.39 (s, 3H), 1.61-1.45 (m, 1H), 0.90 (d, 3H, $J = 6.6$), 0.89 (d, 3H, $J = 6.9$); ^{13}C NMR (75 MHz, CDCl_3) δ 143.6, 138.1, 136.4, 129.5, 127.3, 126.2, 125.5, 121.9, 117.0, 114.6, 52.7, 46.6, 30.8, 21.5, 18.1, 17.7; MS (ESI): m/z 331 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_2\text{S}$: C, 65.42; H, 6.71; N, 8.48; Found: C, 65.52; H, 6.75; N, 8.59.

(3S)-3-(2-Methylsulfanylethyl)-1-tosyl-1,2,3,4-tetrahydro quinoxaline (6g). Yellow, semi-solid; yield, 74%; overall yield, 8.8%; $R_f = 0.52$ (8.0/2.0, hexane/ethylacetate); $[\alpha]_D^{30} +12.03$ (c 0.13, MeOH), HPLC analysis: ee > 99 ($t_R = 11.0$ min, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$); IR $\nu_{\max}$ (KBr, cm^{-1}) 3411, 2928, 2375, 1601, 1493, 1163, 748; ^1H NMR (300 MHz, CDCl_3) δ 7.66 (dd, 1H, $J_1 = 0.9$, $J_2 = 8.1$), 7.51-7.48 (m, 2H), 7.23-7.20 (m, 2H), 7.00-6.95 (m, 1H), 6.73-6.67 (m, 1H), 6.49 (dd, 1H, $J_1 = 1.0$, $J_2 = 8.0$), 4.24 (dd, 1H, $J_1 = 3.0$, $J_2 = 13.7$), 3.96 (bs, 1H), 3.05 (dd, 1H, $J_1 = 10.0$, $J_2 = 13.7$), 2.93-2.85 (m, 1H), 2.57-2.46 (m, 2H), 2.39 (s, 3H), 2.10 (s, 3H), 1.74-1.54 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3) δ 143.6, 137.4, 136.4, 129.6, 127.2, 126.2, 125.2, 122.0, 117.4, 114.8, 48.7, 47.1, 32.7, 30.1, 21.5, 15.6; MS (ESI): m/z 363 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{18}\text{H}_{22}\text{N}_2\text{O}_2\text{S}_2$: C, 59.64; H, 6.12; N, 7.73; Found: C, 59.68; H, 6.19; N, 7.75.

(S)-2-(2-Nitro-phenylamino)-3-phenyl-propan-1-ol (7b). This product was isolated as yellow oil. Yield, 68%, $R_f = 0.50$ (7/3, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3361, 2949, 1618, 1508, 1260, 1027, 744; ^1H NMR (300 MHz, CDCl_3) δ 8.24 (d, 1H, $J = 8.2$), 8.06 (dd, 1H, $J_1 = 1.4$, $J_2 = 8.8$), 7.35-7.16 (m, 6H), 6.86 (d, 1H, $J = 8.6$), 6.58-6.53 (m, 1H), 3.99-3.91 (m, 1H), 3.77-3.67 (m, 2H), 3.05-2.88 (m, 2H), 2.62 (bs, 1H); ^{13}C NMR (50 MHz, CDCl_3) δ 144.9, 137.3, 136.1, 129.2, 128.7, 127.0, 126.8, 115.5, 114.1, 63.4, 55.5, 37.6; MS (ESI): m/z 273 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{15}\text{H}_{16}\text{N}_2\text{O}_3$: C, 66.16; H, 5.92; N, 10.29; Found: C, 66.21; H, 5.85; N, 10.32.

(S)-3-Methyl-2-(2-nitro-phenylamino)-butan-1-ol (7c): This product was isolated as yellow oil. yield, 66%, $R_f = 0.48$ (7/3, hexane/EtOAc), IR $\nu_{\max}$ (neat, cm^{-1}) 3375, 3022, 2364, 1586, 1217, 770; ^1H NMR (300 MHz, CDCl_3) δ 8.10 (d, 1H, $J = 8.7$), 7.98 (dd, 1H, $J_1 = 1.1$, $J_2 = 8.6$), 7.29-7.24 (m, 1H), 6.85 (d, 1H, $J = 8.7$), 6.50-6.45 (m, 1H), 3.70-3.59 (m, 2H), 3.51- 3.43 (m, 1H), 2.44 (bs, 1H), 2.05-1.92 (m, 1H), 0.95 (d, 3H, $J = 6.6$), 0.93 (d, 3H, $J = 6.5$); ^{13}C NMR (50 MHz, CDCl_3) δ 146.1, 136.0, 132.0, 127.1, 115.1, 114.4, 62.8, 59.9, 29.7, 19.6, 18.4; MS (ESI): m/z 225 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{11}\text{H}_{16}\text{N}_2\text{O}_3$: C, 58.91; H, 7.19; N, 12.49; Found: C, 58.98; H, 7.11; N, 12.56.

(S)-2-Benzyl-1,2,3,4-tetrahydroquinoxaline (8b). Brown oil; yield, 68%; overall yield, 10.8%; $R_f = 0.53$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} -293.6$ (c 0.10, MeOH), HPLC analysis: ee > 99 ($t_R = 8.8$ min, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$); IR $\nu_{\max}$ (neat, cm^{-1}) 3426, 3023, 2362, 1638, 1216, 762; ^1H NMR (300 MHz, CDCl_3) δ 7.41-7.26 (m, 5H), 6.64-6.45 (m, 4H), 3.68-3.61 (m, 1H), 3.45-3.40 (m, 3H), 3.20 (dd, 1H, $J_1 = 7.1$, $J_2 = 10.7$), 2.89 (dd, 1H, $J_1 = 5.5$, $J_2 = 13.3$), 2.76 (dd, 1H, $J_1 = 8.5$, $J_2 = 13.3$); ^{13}C NMR (75 MHz, CDCl_3) δ 138.0, 133.2, 133.0, 129.2, 128.6, 126.6, 118.75, 118.68, 114.5, 114.4, 51.2, 46.2, 40.5; MS (ESI): m/z 225 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{15}\text{H}_{16}\text{N}_2$: C, 80.32; H, 7.19; N, 12.49; Found: C, 80.41; H, 7.24; N, 12.41.

(S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (10c). Yellow oil; yield, 73%; $R_f = 0.51$ (8.0/2.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3024, 2959, 1740, 1507, 1216, 1156, 761; ^1H NMR (300 MHz, CDCl_3) δ 8.14-8.11 (m, 2H), 7.65-7.62 (m, 2H), 7.43-7.37 (m, 1H), 7.29-7.21 (m, 7H), 7.05 (dd, 1H, $J = 8.5$), 6.65-6.60 (m, 1H), 4.55-4.39 (m, 2H), 3.54 (dd, 1H, $J_1 = 6.6$, $J_2 = 15.4$), 3.41 (s, 3H), 3.34 (dd, 1H, $J_1 = 7.3$, $J_2 = 15.4$), 3.19 (dd, 1H, $J_1 = 5.3$, $J_2 = 13.8$), 2.73 (dd, 1H, $J_1 = 8.4$, $J_2 = 13.8$), 2.40 (s, 3H), 1.70-1.59 (m, 1H), 1.48-1.39 (m, 2H), 0.91 (d, 3H, $J = 6.1$), 0.90 (d, 3H, $J = 6.3$); ^{13}C NMR (75 MHz, CDCl_3) δ 171.3, 144.8, 143.8, 137.4, 136.1, 135.7, 132.3, 129.5, 129.1, 128.6, 127.5, 126.9, 126.7, 115.5, 114.2, 58.5, 54.3, 52.0, 49.0, 39.4, 39.2, 24.7, 22.4, 21.9, 21.5; MS (ESI): m/z 576 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{29}\text{H}_{35}\text{N}_3\text{O}_6\text{S}$: C, 62.91; H, 6.37; N, 7.59; Found: C, 62.95; H, 6.42; N, 7.61.

(S)-Methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)-3-phenylpropanoate (10d). Yellow oil; yield, 76%; $R_f = 0.50$ (8.0/2.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3021, 2361, 1739, 1509, 1216, 760; ^1H NMR (200 MHz, CDCl_3) δ 8.13-8.06 (m, 2H), 7.55-7.51 (m, 2H), 7.25-7.18 (m, 11H), 7.11-7.07 (m, 2H), 6.94 (d, 1H, $J = 8.6$), 6.64-6.65 (m, 1H), 4.79-4.71 (m, 1H), 4.45-4.31 (m, 1H), 3.55-3.50 (m, 1H), 3.31 (s, 3H), 3.25-3.14 (m, 1H), 3.09-2.99 (m, 2H), 2.86-2.73 (m, 2H), 2.36 (s, 3H); ^{13}C NMR (50 MHz, CDCl_3) δ 170.5, 144.6, 143.8, 137.2, 136.0, 135.9, 135.8, 132.3, 129.5, 129.3, 129.1, 128.9, 128.6, 128.5, 127.4, 127.1, 127.0, 126.8, 126.7, 115.5, 114.2, 61.5, 54.0, 52.0, 48.9, 39.6, 36.4, 21.4; MS (ESI): m/z 587 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{32}\text{H}_{33}\text{N}_3\text{O}_6\text{S}$: C, 65.40; H, 5.66; N, 7.15; Found: C, 65.48; H, 5.64; N, 7.21.

(S)-Methyl-3-methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)-3-phenylpropyl)phenylsulfonamido)butanoate (10b). Yellow oil; yield, 72%; $R_f = 0.53$ (8.0/2.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3021, 2360, 1736, 1601, 1216, 761; ^1H NMR (300 MHz, CDCl_3) δ 8.12-8.07 (m, 2H), 7.63-7.61 (m, 2H), 7.33-7.21 (m, 6H), 7.15-7.13 (m, 2H), 6.85 (d, 1H, $J = 8.9$), 6.62-6.57 (m, 1H), 4.46-4.37 (m, 1H), 4.15-4.10 (m, 1H), 3.63-3.58 (m, 2H), 3.48 (s, 3H), 3.11 (dd, 1H, $J_1 = 5.5$, $J_2 = 14.0$), 2.78 (dd, 1H, $J_1 = 7.3$, $J_2 = 14.0$), 2.34 (s, 3H), 2.03-1.98 (m, 1H), 0.98 (d, 3H, $J = 6.5$), 0.89 (d, 3H, $J = 6.5$); ^{13}C NMR (75 MHz, CDCl_3) δ 171.1, 144.5, 143.6, 137.2, 136.4, 135.9, 132.2, 129.6, 129.3, 129.1, 128.6, 127.3, 127.2, 127.0, 126.8, 115.3, 113.9, 66.2, 53.2, 51.7, 48.5, 39.3, 29.0, 21.5, 19.9, 19.2; MS (ESI): m/z 562 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{28}\text{H}_{33}\text{N}_3\text{O}_6\text{S}$: C, 62.32; H, 6.16; N, 7.79; Found: C, 62.43; H, 6.19; N, 7.75.

(S)-Methyl-2-(4-methyl-N-((S)-2-(2-nitrophenylamino)propyl)phenylsulfonamido)propanoate (10e). Yellow semi-solid; yield, 74%; $R_f = 0.51$ (8.0/2.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3360, 3023, 2923, 1742, 1507, 1346, 760; ^1H NMR (300 MHz, CDCl_3) δ 8.17 (dd, 1H, $J_1 = 1.5$, $J_2 = 8.6$), 7.99 (d, 1H, $J = 7.7$), 7.67-7.65 (m, 2H), 7.52-7.46 (m, 1H), 7.25-7.22 (m, 2H), 7.15 (d, 1H, $J = 8.6$), 6.70-6.64 (m, 1H), 4.67 (q, 1H, $J = 7.3$), 4.30-4.23 (m, 1H), 3.55 (dd, 1H, $J_1 = 5.7$, $J_2 = 15.0$), 3.45 (s, 3H), 3.07 (dd, 1H, $J_1 = 8.8$, $J_2 = 15.0$), 2.38 (s, 3H), 1.46 (d, 3H, $J = 7.3$), 1.37 (d, 3H, $J = 6.3$); ^{13}C NMR (50 MHz, CDCl_3) δ 171.5, 144.5, 143.8, 136.3, 135.9, 129.5, 127.3, 126.9, 115.5, 114.3, 55.9, 52.1, 50.2, 47.8, 21.5, 18.9, 17.1; MS (ESI): m/z 436 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{20}\text{H}_{25}\text{N}_3\text{O}_6\text{S}$: C, 55.16; H, 5.79; N, 9.65; Found: C, 55.11; H, 5.75; N, 9.69.

(S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)phenyl sulfonamido)pentanoate (11c). Brown oil; yield, 66%, (based on two steps); R_f = 0.53 (7.5/2.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3419, 3022, 1738, 1216, 760; ^1H NMR (300 MHz, CDCl_3) δ 7.76-7.73 (m, 2H), 7.53-7.50 (m, 2H), 7.33-7.12 (m, 9H), 7.09-7.05 (m, 2H), 6.63-6.54 (m, 3H), 4.61-4.58 (m, 1H), 4.48-4.44 (m, 1H), 3.70-3.67 (m, 1H), 3.39 (dd, 1H, $J_1 = 3.8$, $J_2 = 15.6$), 3.31 (s, 3H), 3.11 (dd, 1H, $J_1 = 9.6$, $J_2 = 15.6$), 2.74 (dd, 1H, $J_1 = 4.6$, $J_2 = 14.0$), 2.43 (s, 3H), 2.39 (s, 3H), 2.11 (dd, 1H, $J_1 = 8.6$, $J_2 = 14.0$), 1.62-1.38 (m, 3H), 0.82 (d, 3H, $J = 6.1$), 0.81 (d, 3H, $J = 5.8$); ^{13}C NMR (75 MHz, CDCl_3) δ 172.1, 143.6, 143.4, 142.8, 137.9, 137.4, 136.1, 129.4, 129.0, 128.6, 128.4, 128.3, 127.5, 127.4, 126.5, 121.6, 117.0, 111.2, 57.9, 54.3, 52.0, 48.0, 39.1, 38.7, 24.2, 22.6, 21.54, 21.48; MS (ESI): m/z 700 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{36}\text{H}_{43}\text{N}_3\text{O}_6\text{S}_2$: C, 63.79; H, 6.39; N, 6.20; Found: C, 63.81; H, 6.42; N, 6.28.

(S)-Methyl-2-(4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)-3-phenylpropanoate (11d). Brown oil; yield, 62%, (based on two steps); R_f = 0.51 (7.5/2.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3022, 2926, 2360, 1738, 1600, 1216, 759; ^1H NMR (200 MHz, CDCl_3) δ 7.75-7.71 (m, 2H), 7.37-7.07 (m, 16H), 7.02-6.92 (m, 3H), 6.61-6.53 (m, 3H), 4.76-4.69 (m, 1H), 4.50-4.46 (m, 1H), 3.82-3.78 (m, 1H), 3.22 (s, 3H), 3.18-3.05 (m, 2H), 2.83-2.72 (m, 2H), 2.41 (s, 3H), 2.36 (s, 3H), 2.28-2.09 (m, 2H); ^{13}C NMR (50 MHz, CDCl_3) δ 171.3, 143.5, 142.9, 137.9, 137.3, 136.1, 129.5, 129.4, 129.1, 128.9, 128.61, 128.56, 128.4, 128.2, 127.6, 127.4, 126.9, 126.5, 121.9, 117.3, 111.8, 61.2, 54.2, 52.1, 48.3, 39.1, 36.1, 21.55, 21.48; MS (ESI): m/z 712 $[\text{M} + \text{H}]^+$, 734 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{39}\text{H}_{41}\text{N}_3\text{O}_6\text{S}_2$: C, 65.80; H, 5.81; N, 5.90; Found: C, 65.86; H, 5.86; N, 5.95.

N-((S)-1-Hydroxy-4-methylpentan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenyl propyl)benzenesulfonamide (12c). Brown oil; yield, 65%; $R_f = 0.54$ (4.0/3.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3692, 3021, 2361, 1216, 763; ^1H NMR (300 MHz, CDCl_3) δ 7.69-7.66 (m, 2H), 7.39-7.24 (m, 9H), 7.15-7.05 (m, 4H), 6.84 (d, 1H, $J = 8.1$), 6.55-6.48 (m, 2H), 4.32-4.29 (m, 1H), 3.99-3.94 (m, 1H), 3.70 (dd, 1H, $J_1 = 3.7$, $J_2 = 12.2$), 3.57-3.53 (m, 1H), 3.23 (dd, 1H, $J_1 = 2.4$, $J_2 = 15.2$), 3.01 (dd, 1H, $J_1 = 4.0$, $J_2 = 14.0$), 2.86 (dd, 1H, $J_1 = 10.4$, $J_2 = 15.1$), 2.42-2.33 (m, 7H), 1.41-1.35 (m, 1H), 1.19-1.13 (m, 2H), 0.79 (d, 3H, $J = 6.6$), 0.75 (d, 3H, $J = 6.6$); MS (ESI): m/z 650 $[\text{M} + \text{H}]^+$, 672 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{35}\text{H}_{43}\text{N}_3\text{O}_5\text{S}_2$: C, 64.69; H, 6.67; N, 6.47; Found: C, 64.65; H, 6.72; N, 6.56.

N-((S)-1-Hydroxy-3-phenylpropan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)-3-phenyl propyl)benzenesulfonamide (12d). Brown oil; yield, 64%; $R_f = 0.52$ (7.0/3.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3661, 3022, 2927, 1600, 1216, 759; ^1H NMR (300 MHz, CDCl_3) δ 7.68-7.65 (m, 2H), 7.42-7.37 (m, 4H), 7.32-7.19 (m, 9H), 7.11-7.09 (m, 3H), 7.05-7.02 (m, 2H), 6.94-6.91 (m, 2H), 6.52-6.51 (m, 1H), 4.41 (bs, 1H), 4.18-4.11 (m, 1H), 3.58-3.53 (m, 2H), 3.41-3.35 (m, 1H), 3.09-3.00 (m, 2H), 2.60-2.46 (m, 2H), 2.42 (s, 3H), 2.40-2.38 (m, 1H), 2.34 (s, 3H); ^{13}C NMR (75 MHz, CDCl_3) δ 144.5, 143.9, 143.4, 138.0, 137.4, 136.5, 136.2, 129.6, 129.3, 129.1, 129.0, 128.6, 128.1, 127.7, 127.3, 126.6, 126.5, 122.2, 118.1, 113.5, 61.9, 61.7, 55.3, 47.3, 39.6, 35.0, 21.6, 21.5; MS (ESI): m/z 684 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{38}\text{H}_{41}\text{N}_3\text{O}_5\text{S}_2$: C, 66.74; H, 6.04; N, 6.14; Found: C, 66.71; H, 6.11; N, 6.10.

N-((S)-1-Hydroxypropan-2-yl)-4-methyl-N-((S)-2-(2-(4-methylphenylsulfonamido)phenylamino)propyl)benzenesulfonamide (12e). Brown oil; yield, 57%, (based on three steps); R_f = 0.46 (7.0/3.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3663, 3023, 2928, 1597, 1216, 761; ^1H NMR (300 MHz, CDCl_3) δ 7.71-7.69 (m, 2H), 7.64-7.61 (m, 2H), 7.27-7.17 (m, 5H), 7.09-7.04 (m, 1H), 6.70 (d, 1H, J = 7.9), 6.61 (dd, 1H, J_1 = 1.4, J_2 = 7.8), 6.53-6.47 (m, 1H), 4.08-3.99 (m, 2H), 3.63-3.54 (m, 2H), 3.32 (dd, 1H, J_1 = 3.6, J_2 = 15.2), 2.82 (dd, 1H, J_1 = 10.1, J_2 = 15.2), 2.39 (s, 3H), 2.35 (s, 3H), 1.93 (bs, 1H), 1.04 (d, 3H, J = 6.3), 0.84 (d, 3H, J = 6.8); ^{13}C NMR (50 MHz, CDCl_3) δ 143.9, 143.6, 143.4, 137.23, 136.19, 129.6, 129.4, 128.6, 127.8, 127.4, 127.1, 122.5, 117.9, 113.1, 63.9, 55.8, 49.1, 48.7, 21.5, 21.4, 18.2, 13.4; MS (ESI): m/z 532 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{26}\text{H}_{33}\text{N}_3\text{O}_5\text{S}_2$: C, 58.73; H, 6.26; N, 7.90; Found: C, 58.78; H, 6.18; N, 7.94.

N-((S)-1-Hydroxy-3-methylbutan-2-yl)-4-methyl-N-((S)-3-methyl-2-(2-(4-methylphenylsulfonamido)phenylamino) butyl)benzenesulfonamide (12f). Brown oil; yield, 54%, (based on three steps); R_f = 0.50 (7.0/3.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3667, 3029, 2929, 1603, 1217, 759; ^1H NMR (300 MHz, CDCl_3) δ 7.70-7.63 (m, 4H), 7.28-7.23 (m, 2H), 7.07-7.05 (m, 2H), 6.95-6.90 (m, 1H), 6.77 (bs, 1H), 6.55-6.40 (m, 2H), 6.19 (d, 1H, J = 8.0), 4.84 (bs, 1H), 3.71-3.60 (m, 4H), 3.38 (bs, 1H), 3.07-2.99 (m, 1H), 2.40 (s, 3H), 2.29 (s, 3H), 1.89-1.87 (m, 2H), 0.99-0.97 (m, 6H), 0.85 (d, 3H, J = 6.7), 0.82 (d, 3H, J = 6.9); ^{13}C NMR (50 MHz, CDCl_3) δ 144.1, 143.7, 142.9, 139.2, 136.5, 129.5, 129.3, 128.4, 128.0, 127.5, 127.0, 121.7, 117.1, 112.8, 67.0, 62.3, 55.8, 45.2, 29.8, 27.7, 21.5, 21.4, 20.7, 20.2, 18.6, 16.6; MS (ESI): m/z 588 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{30}\text{H}_{41}\text{N}_3\text{O}_5\text{S}_2$: C, 61.30; H, 7.03; N, 7.15; Found: C, 61.36; H, 7.11; N, 7.10.

(3S,6S)-6-Benzyl-3-isopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (13b).

Light brown semi-solid; yield, 73%; $R_f = 0.50$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} -147.0$ (c 0.11, MeOH), HPLC analysis: ee > 99 ($t_R = 21.0$ min, hexane/propanol); IR $\nu_{\max}$ (KBr, cm^{-1}) 3024, 2926, 2869, 1493, 1217, 765; ^1H NMR (300 MHz, CDCl_3) δ 8.24 (bs, 1H), 7.79-7.76 (m, 2H), 7.61 (dd, 1H, $J_1 = 1.0$, $J_2 = 8.1$), 7.49-7.46 (m, 2H), 7.28-7.20 (m, 7H), 7.17-7.11 (m, 1H), 7.01-6.96 (m, 1H), 6.79-6.76 (m, 3H), 3.62-3.56 (m, 2H), 2.92-2.83 (m, 1H), 2.73-2.69 (m, 1H), 2.64-2.59 (m, 1H), 2.58-2.52 (m, 1H), 2.47-2.42 (m, 4H), 2.27 (s, 3H), 2.17-2.11 (m, 1H), 1.55-1.54 (m, 1H), 1.04-1.02 (m, 6H); ^{13}C NMR (75 MHz, CDCl_3) δ 144.2, 143.1, 138.3, 137.8, 136.7, 134.9, 129.7, 128.6, 128.4, 127.1, 127.0, 126.6, 123.8, 122.9, 116.8, 59.8, 59.6, 54.3, 45.5, 36.5, 26.1, 21.5, 21.4, 20.1, 19.8; MS (ESI): m/z 618 $[\text{M} + \text{H}]^+$, 640 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{34}\text{H}_{39}\text{N}_3\text{O}_4\text{S}_2$: C, 66.10; H, 6.36; N, 6.80; Found: C, 66.17; H, 6.42; N, 6.88.

(3S,6S)-6-Benzyl-3-isobutyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (13c).

Colorless semi-solid; yield, 74%; $R_f = 0.52$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} -40.0$ (c 0.10, MeOH), HPLC analysis: ee > 99 ($t_R = 16.1$ min, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$); IR $\nu_{\max}$ (KBr, cm^{-1}) 3029, 2926, 1493, 1340, 1163, 753; ^1H NMR (300 MHz, CDCl_3) δ 8.16 (bs, 1H), 7.75-7.73 (m, 2H), 7.67 (d, 1H, $J = 8.1$), 7.52-7.49 (m, 2H), 7.27-7.14 (m, 8H), 7.04-7.00 (m, 1H), 6.89 (d, 1H, $J = 7.8$), 6.82-6.80 (m, 2H), 4.10-4.07 (m, 1H), 3.59-3.55 (m, 1H), 2.90 (dd, 1H, $J_1 = 10.8$, $J_2 = 14.0$), 2.80-2.77 (m, 1H), 2.73-2.67 (m, 1H), 2.46 (s, 3H), 2.33-2.29 (m, 4H), 2.23 (dd, 1H, $J_1 = 2.9$, $J_2 = 13.9$), 1.80-1.69 (m, 2H), 1.53-1.44 (m, 2H), 1.01 (d, 3H, $J = 6.4$), 0.98 (d, 3H, $J = 6.5$); ^{13}C NMR (75 MHz, CDCl_3) δ 144.1, 143.3, 138.1, 137.8, 136.7, 134.9, 129.65, 129.62, 128.6, 128.4, 127.1, 126.9, 126.6, 124.1, 123.0, 117.6, 59.8, 57.2, 51.4, 45.0, 38.3, 36.6, 24.8, 22.6, 22.3, 21.5, 21.4; MS (ESI): m/z 632 $[\text{M} + \text{H}]^+$, 654 $[\text{M} + \text{Na}]^+$; Anal. calcd. (%) for $\text{C}_{35}\text{H}_{41}\text{N}_3\text{O}_4\text{S}_2$: C, 66.53; H, 6.54; N, 6.65; Found: C, 66.61; H, 6.58; N, 6.61.

(3S,6S)-3,6-Dibenzyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7] triazonine (13d). Brown semi-solid; yield, 73%; $R_f = 0.51$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} +64.6$ (c 0.11, MeOH), HPLC analysis: ee > 99 ($t_R = 16.0$ min, CH₃CN/H₂O); IR $\nu_{\max}$ (KBr, cm⁻¹) 3022, 2361, 1493, 1216, 1161, 760; ¹H NMR (300 MHz, CDCl₃) δ 8.34 (bs, 1H), 7.80-7.77 (m, 2H), 7.64 (d, 1H, $J = 7.8$), 7.41-7.38 (m, 2H), 7.31-7.14 (m, 13H), 7.07-7.02 (m, 2H), 6.84-6.82 (m, 2H), 4.34 (bs, 1H), 3.66-3.56 (m, 1H), 3.15-3.07 (m, 1H), 3.03-2.96 (m, 3H), 2.81-2.76 (m, 1H), 2.50-2.38 (m, 4H), 2.34-2.20 (m, 5H); ¹³C NMR (75 MHz, CDCl₃) δ 144.2, 143.3, 137.9, 137.4, 137.3, 136.7, 136.6, 135.0, 129.72, 129.66, 129.1, 128.8, 128.6, 128.5, 127.3, 127.04, 127.00, 126.6, 124.1, 123.4, 117.2, 60.9, 55.9, 54.6, 45.3, 36.6, 35.4, 21.5, 21.4; MS (ESI): m/z 666 [M + H]⁺; Anal. calcd. (%) for C₃₈H₃₉N₃O₄S₂: C, 68.54; H, 5.90; N, 6.31; Found: C, 68.59; H, 5.97; N, 6.36.

(3S,6S)-3,6-Dimethyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7] triazonine (13e). Brown oil; yield, 75%; $R_f = 0.51$ (8.0/2.0, hexane/EtOAc); $[\alpha]_D^{30} +44.5$ (c 0.10, MeOH), IR $\nu_{\max}$ (neat, cm⁻¹) 3244, 3026, 2925, 1493, 1335, 1161, 766; ¹H NMR (300 MHz, CDCl₃) δ 8.13 (s, 1H), 7.73-7.66 (m, 4H), 7.60 (d, 1H, $J = 8.1$), 7.35-7.32 (m, 2H), 7.21-7.18 (m, 2H), 7.01-6.99 (m, 2H), 4.15 (bs, 1H), 3.76-3.72 (m, 1H), 2.93-2.79 (m, 3H), 2.45 (s, 3H), 2.35 (s, 3H), 2.17-2.13 (m, 1H), 1.20 (d, 3H, $J = 6.6$), 0.59 (d, 3H, $J = 5.2$); ¹³C NMR (75 MHz, CDCl₃) δ 143.9, 143.4, 138.2, 137.4, 136.4, 134.7, 129.8, 129.5, 127.0, 126.9, 126.8, 124.0, 123.3, 117.4, 59.5, 55.2, 48.9, 46.7, 21.44, 21.40, 16.2, 14.3; MS (ESI): m/z 514 [M + H]⁺; Anal. calcd. (%) for C₂₆H₃₁N₃O₄S₂: C, 60.79; H, 6.08; N, 8.18; Found: C, 60.73; H, 6.14; N, 8.12.

(3S,6S)-3,6-Di-isopropyl-1,4-ditosyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7] triazonine (13f).

Light brown oil; yield, 76%; $R_f = 0.51$ (7.5/2.5, hexane/EtOAc); $[\alpha]_D^{30} +74.6$ (c 0.11, MeOH), IR $\nu_{\max}$ (neat, cm^{-1}) 3234, 3029, 2362, 1493, 1217, 763; ^1H NMR (300 MHz, CDCl_3) δ 8.23 (s, 1H), 7.82-7.73 (m, 3H), 7.44-7.23 (m, 5H), 7.09-7.01 (m, 1H), 6.93-6.84 (m, 1H), 6.71-6.66 (m, 1H), 3.84-3.76 (m, 1H), 3.54-3.48 (m, 1H), 3.12-2.99 (m, 1H), 2.78-2.72 (m, 1H), 2.61-2.54 (m, 1H), 2.46 (s, 3H), 2.41-2.40 (m, 1H), 2.37 (s, 3H), 1.48-1.44 (m, 1H), 1.19-1.14 (m, 1H), 1.08 (d, 3H, $J = 6.5$), 0.98 (d, 3H, $J = 6.5$), 0.76 (d, 3H, $J = 7.1$), 0.50 (d, 3H, $J = 6.9$); ^{13}C NMR (50 MHz, CDCl_3) δ 144.0, 143.3, 138.7, 136.9, 136.7, 134.1, 129.7, 129.6, 127.2, 127.1, 126.5, 123.0, 122.9, 115.5, 61.2, 59.7, 55.1, 40.3, 26.4, 26.3, 21.5, 20.2, 19.8, 19.2, 15.1; MS (ESI): m/z 570 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{30}\text{H}_{39}\text{N}_3\text{O}_4\text{S}_2$: C, 63.24; H, 6.90; N, 7.37; Found: C, 63.29; H, 6.94; N, 7.45.

(2S,5S)-2,5-Dibenzyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (14c). Brown oil; yield 68%; overall yield, 6.6%; $R_f = 0.51$ (0.5/9.5, MeOH- CHCl_3); $[\alpha]_D^{30} +34.7$ (c 0.10, MeOH), HPLC analysis: ee > 99 ($t_R = 7.7$ min, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$); IR $\nu_{\max}$ (neat, cm^{-1}) 3451, 3022, 1637, 1216, 766, 760; ^1H NMR (300 MHz, CDCl_3) δ 7.28-7.11 (m, 10H), 7.07-7.02 (m, 2H), 6.86-6.84 (m, 2H), 3.16-3.11 (m, 2H), 2.96-2.76 (m, 6H), 2.69-2.65 (m, 1H), 2.50-2.46 (m, 1H); ^{13}C NMR (75 MHz, CDCl_3) δ 139.6, 138.2, 136.6, 129.5, 129.1, 129.0, 128.6, 128.2, 126.9, 126.4, 125.9, 123.9, 123.8, 117.8, 60.3, 56.1, 53.3, 46.2, 38.8; MS (ESI): m/z 358 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{24}\text{H}_{27}\text{N}_3$: C, 80.63; H, 7.61; N, 11.75; Found: C, 80.68; H, 7.71; N, 11.70.

(2S,5S)-2,5-Dimethyl-2,3,4,5,6,7-hexahydro-1H-benzo[b][1,4,7]triazonine (14d). Brown oil; yield 66%; overall yield, 8.9%; $R_f = 0.51$ (2.0/8.0, MeOH/ CHCl_3); IR $\nu_{\max}$ (neat, cm^{-1}) 3233, 2928, 1596, 1453, 763; ^1H NMR (200 MHz, CDCl_3) δ 6.96-6.89 (m, 2H), 6.76-6.70 (m, 2H), 3.65-3.64 (bs, 2H), 3.37-3.23 (m, 1H), 3.18-3.02 (m, 2H), 2.97-2.87 (m, 2H), 2.76-2.69 (m, 2H), 1.25 (d, 3H, $J = 6.5$), 0.95 (d, 3H, $J = 6.5$); ^{13}C NMR (50 MHz, CDCl_3) δ 142.2, 137.5, 124.6, 122.4, 118.2, 115.1, 53.8, 50.6, 49.9, 18.5; MS (ESI): m/z 206 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{12}\text{H}_{19}\text{N}_3$: C, 70.20; H, 9.33; N, 20.47; Found: C, 70.24; H, 9.41; N, 20.53.

(2*S*,5*S*)-2,5-Di-isopropyl-2,3,4,5,6,7-hexahydro-1*H*-benzo[*b*] [1,4,7]triazonine (14e).

Brown oil; yield 64%; overall yield, 8.8%; $R_f = 0.51$ (1.2/8.8, MeOH/CHCl₃); IR $\nu_{\max}$ (neat, cm⁻¹) 3236, 3022, 2923, 1597, 1216, 760; ¹H NMR (300 MHz, CDCl₃) δ 7.07 (d, 1H, $J = 7.9$), 6.95-6.90 (m, 1H), 6.75-6.70 (m, 2H), 3.08-2.82 (m, 6H), 2.31-2.19 (m, 1H), 2.05-1.96 (m, 1H), 1.02-0.97 (m, 6H), 0.83 (d, 3H, $J = 7.0$), 0.79 (d, 3H, $J = 6.8$); ¹³C NMR (50 MHz, CDCl₃) δ 142.4, 137.8, 124.6, 122.8, 118.3, 115.4, 62.4, 59.6, 54.2, 41.4, 26.9, 26.7, 20.05, 19.99, 19.2, 17.3; MS (ESI): m/z 262 [M + H]⁺; Anal. calcd. (%) for C₁₆H₂₇N₃; C, 73.51; H, 10.41; N, 16.07; Found: C, 73.58; H, 10.44; N, 16.13.

(*S*)-Methyl-2-(*N*-((*S*)-2-(2-(*N*-((*S*)-2-(tert-butoxycarbonylamino)-3-phenyl-propyl)-4-methylphenylsulfonamido)phenylamino)-3-phenylpropyl)-4-methylphenylsulfonamido)-4-methylpentanoate (16b). Colorless oil; yield, 64%; $R_f = 0.51$ (7.5/2.5, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm⁻¹) 3407, 3021, 2957, 2359, 1714, 1738, 1342, 1217, 767; ¹H NMR (300 MHz, CDCl₃) δ 7.76 (d, 1H, $J = 8.2$), 7.60 (d, 1H, $J = 8.2$), 7.52-7.45 (m, 2H), 7.31-7.08 (m, 14H), 6.97 (d, 1H, $J = 7.9$), 6.85-6.79 (m, 1H), 6.48-6.37 (m, 1H), 6.31-6.24 (m, 1H), 5.20-5.03 (m, 1H), 4.62-4.52 (m, 2H), 4.40-4.31 (m, 1H), 4.20-4.10 (m, 1H), 3.87-3.83 (m, 1H), 3.61 (dd, 1H, $J_1 = 4.1$, $J_2 = 15.3$), 3.50 (s, 3H), 3.43-3.40 (m, 2H), 3.30 (bs, 1H), 3.15 (dd, 1H, $J_1 = 9.8$, $J_2 = 15.3$), 2.87-2.86 (m, 1H), 2.44 (s, 6H), 1.79-1.61 (m, 3H), 1.37 (s, 9H), 0.93-0.89 (m, 6H); ¹³C NMR (75 MHz, CDCl₃) δ 171.6, 146.1, 143.5, 143.3, 139.1, 137.8, 136.3, 129.5, 129.3, 128.5, 128.4, 128.3, 128.1, 127.9, 126.3, 116.5, 112.1, 58.6, 53.1, 52.0, 49.1, 39.4, 39.1, 38.8, 28.5, 28.4, 24.8, 22.7, 22.5, 22.1, 21.6; MS (ESI): m/z 911 [M + H]⁺; Anal. calcd. (%) for C₅₀H₆₂N₄O₈S₂; C, 65.91; H, 6.86; N, 6.15; Found: C, 65.96; H, 6.91; N, 6.21.

(S)-Methyl-4-methyl-2-(4-methyl-N-((S)-2-(2-(4-methyl-N-((S)-2-(4-methylphenylsulfonamido)-3-phenylpropyl)phenylsulfonamido)phenylamino)-3-phenylpropyl)phenylsulfonamido)pentanoate (18b). Brown oil; yield, 58%, (based on two steps); $R_f = 0.51$ (7.0/3.0, hexane/EtOAc); IR $\nu_{\max}$ (neat, cm^{-1}) 3383, 3022, 2359, 1736, 1342, 1215, 760; ^1H NMR (300 MHz, CDCl_3) δ 7.73 (d, 1H, $J = 8.1$), 7.61 (d, 1H, $J = 8.2$), 7.51-7.47 (m, 2H), 7.38 (d, 1H, $J = 8.2$), 7.32-6.98 (m, 17H), 6.84-6.82 (m, 1H), 6.53-6.45 (m, 3H), 6.27-6.20 (m, 1H), 5.03-5.01 (m, 1H), 4.58-4.54 (m, 1H), 4.35-4.29 (m, 1H), 4.20-4.12 (m, 1H), 3.63-3.54 (m, 1H), 3.47 (s, 3H), 3.30-3.22 (m, 3H), 3.13-2.99 (m, 2H), 2.92-2.89 (m, 1H), 2.69-2.67 (m, 1H), 2.47 (s, 3H), 2.42 (s, 3H), 2.38 (s, 3H), 1.68-1.61 (m, 1H), 1.41-1.31 (m, 2H), 0.93 (d, 3H, $J = 6.0$), 0.90 (d, 3H, $J = 6.2$); ^{13}C NMR (75 MHz, CDCl_3) δ 171.7, 146.3, 143.8, 143.1, 142.7, 138.6, 136.5, 136.4, 136.3, 134.1, 129.4, 129.1, 128.65, 128.58, 128.5, 128.4, 128.3, 127.9, 127.3, 127.2, 126.3, 126.24, 126.16, 125.7, 116.5, 112.6, 58.4, 54.9, 53.5, 53.1, 52.0, 48.7, 39.5, 38.8, 38.1, 24.6, 22.0, 21.7, 21.6, 21.5; MS (ESI): m/z 965 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{52}\text{H}_{60}\text{N}_4\text{O}_8\text{S}_3$: C, 64.70; H, 6.27; N, 5.80; Found: C, 64.78; H, 6.23; N, 5.89.

(3S,6S,9S)-3,9-Dibenzyl-6-isobutyl-1,4,7-tritosyl-1,2,3,4,5,6,7,8,9,10-decahydrobenzo[b][1,4,7,10]tetraaza-cyclododecine (20b). Light brown, semi-solid; yield, 49%, (based on two steps); overall yield, 3.9%; $R_f = 0.52$ (7.5/2.5, hexane/EtOAc); $[\alpha]_{\text{D}}^{30} -168.7$ (c 0.10, MeOH), HPLC analysis: ee > 99 ($t_R = 17.5$ min, $\text{CH}_3\text{CN}/\text{H}_2\text{O}$); IR $\nu_{\max}$ (KBr, cm^{-1}) 3021, 2928, 2361, 1216, 761; ^1H NMR (300 MHz, CDCl_3) δ 7.56-7.48 (m, 4H), 7.42-7.40 (m, 2H), 7.35-7.16 (m, 12H), 7.09-7.00 (m, 5H), 6.89-6.87 (m, 2H), 6.73 (dd, 1H, $J_1 = 1.2$, $J_2 = 8.0$), 4.94-4.92 (m, 1H), 4.36-4.29 (m, 2H), 4.26-4.18 (m, 2H), 4.07-4.00 (m, 2H), 3.59-3.56 (m, 1H), 3.41-3.30 (m, 2H), 3.01-2.87 (m, 2H), 2.78-2.68 (m, 2H), 2.47 (s, 3H), 2.44 (s, 3H), 2.25 (s, 3H), 1.74-1.64 (m, 3H), 0.97 (d, 3H, $J = 6.2$), 0.95 (d, 3H, $J = 6.3$); ^{13}C NMR (75 MHz, CDCl_3) δ 149.3, 144.1, 143.4, 142.9, 138.3, 137.4, 136.9, 136.5, 135.9, 135.6, 130.4, 129.8, 129.7, 129.6, 129.2, 128.9, 128.8, 128.6, 128.5, 128.4, 127.2, 127.1, 126.7, 125.8, 124.7, 59.6, 58.9, 54.1, 52.3, 51.6, 44.6, 38.7, 38.6, 36.4, 24.4, 23.4, 23.3, 21.6, 21.5, 21.3; MS (ESI): m/z 919 $[\text{M} + \text{H}]^+$; Anal. calcd. (%) for $\text{C}_{51}\text{H}_{58}\text{N}_4\text{O}_6\text{S}_3$: C, 66.64; H, 6.36; N, 6.10; Found: C, 66.60; H, 6.41; N, 6.19.